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General background 
 
1. Gastrointestinal Stromal Tumor 
1.1. Brief history of GISTs 
Gastrointestinal stromal tumors (GISTs) are rare sarcomas, which represent the most common 
mesenchymal tumor of the gastrointestinal (GI) tract 1. Three milestones have characterized the 
history of GISTs. In 1941, for the first time, Golden and Stout characterized a group of 
mesenchymal tumor arising in the bowel wall 2, but in 1983 Mazur and Clark proposed the term 
“stromal tumor” for this specific disease 3. The second milestone was in 1998, when a 
groundbreaking publication by Hirota and colleagues reported activating mutations in the KIT 
receptor tyrosine kinase (RTK) gene in GISTs as well as expression of KIT protein by 
immunohistochemistry (IHC) 4. Finally, the last milestone took place with the introduction of 
tyrosine kinase receptor inhibitor (TKI), imatinib, which led to a terrific improvement of GIST 
patients’ prognosis 5. 
1.2.  Epidemiology, clinical features and prognosis of GISTs 
Even if rare, GISTs represent the most common mesenchymal neoplasia of the GI tract. The true 
incidence of GIST in the US and Europe is hard to determine, as GISTs have only been accurately 
recognized and diagnosed as an entity since the late ‘90s. The incidence of these tumors is 
geographically variable, from 4.3–6.8 cases per million to 19–22 cases per million 6. It is estimated 
that incidence rates of GIST in US is 11-14 cases/ 1000000 with 4000-6000 new cases per 
year 7; similar incidence rates have been found in Europe 8,9.  
Regarding to sex differences, there is a slight prevalence in males. The median age is around 60–
65 years, but cases in patients younger than 40 are rare, and only 1% interest patients aged < 21. 
However, pediatric GISTs represent a clinically and molecularly distinct subset 10,11.  
GISTs occur throughout the GI tract and are most commonly found in the stomach (60%), small 
intestine (35%, specifically, jejunum and ileum (30%) and duodenum (5%)), colorectum (4%), and 
rarely in the esophagus and appendix (Figure 1) 10,12,13.  
 
 
The tumors are generally between 1 and 40 cm in diameter at the time of diagnosis and may cause 
mass-related symptoms or anemia as a result of mucosal ulceration 14. Patients with GIST, often, do 
not experience any specific symptoms or signs and when symptoms do occur, they may be vague. 
Clinical symptoms associated with GIST include abdominal pain, fatigue, dysphagia, satiety, 
nausea and vomiting, vomiting blood, blood in the stool and obstruction. Patients may present with 
chronic GI bleeding (causing anemia), or acute GI bleeding (caused by erosion through the gastric 
or bowel mucosa) or rupture into the abdominal cavity causing life-threatening intraperitoneal 
hemorrhage. It is not uncommon that a GIST is discovered by chance when a person has an imaging 
test for an unrelated concern or condition 15.  
Figure 1. GISTs may be found anywhere in or near the  GI tract 
1.3. Histopathology 
As mentioned above, GISTs – commonly arising within the muscle of GI tract – may range from 1 
cm to more than 40 cm in size, and 5 cm is considered the average size.  
GISTs probably originate from the interstitial cells of Cajal (ICC) or their precursors 16. ICCs 
generate a periodic depolarization – referred to as pacemaker activity – in the GI tract controlling 
intestinal motility 16,17. Moreover, similar to GISTs, ICCs express the RTK KIT, encoded by c-KIT 
gene. In general, small GISTs tend to form intramural masses, while larger GISTs make external 
masses and involve muscular layers 14. Morphologically, it is possible to distinguish three main 
histological subtypes in GISTs: i) spindle cell type (~70% of the cases), ii) epithelioid type (~20%), 
and iii) mixed spindle cell and epithelioid type (~10%) (Figure 2). The spindle cells are 
monomorphic, with rounded to elongated nuclei and made up of cells in short fascicles. Epithelioid 
cell GISTs are characterized by round cells arranged in nests or sheets and with eosinophilic to clear 
cytoplasm; cells are polygonal with round, centrally located nuclei. Finally, approximately 10% of 
GISTs show mixed morphology, being composed of both spindle and epithelioid cells 18. 
 
Figure 2. Example of GIST cells’ morphology. A) GIST composed of spindle cells (hematoxylin-eosin, original 
magnification ×200). B) GIST composed of epithelioid cells (hematoxylin-eosin, original magnification ×200) 18 
 
 
 1.4. Oncogenic mutations in KIT and PDGFRA genes 
With the identification of the specific mutation in KIT gene in 1998 by Hirota et al 4, the history of 
this tumor was completely changed. Today, it is well established that about 80-85% of GISTs 
harbor a gain of function mutation in KIT or PDGFRA genes. KIT and PDGFRA genes are  
  
Figure 3. Structure of RTK 
 
adjacently located on chromosome 4q12 and 
encode RTK class 3. KIT and PDGFRA 
receptors share structural features and are 
composed of an extracellular (EC) ligand-
binding domain, a transmembrane domain, a 
juxtamembrane domain (JM), and two 
cytoplasmic kinase domains (TK1, which 
includes ATP binding pocket, and TK2, the 
kinase activation loop) (Figure 3) 19,20. In 
physiological conditions, KIT and PDGFRA 
are activated by binding of their ligands to the  
 EC domain, stem cell factor (SCF) and Platelet Derived Growth Factor Subunit A (PDGFA), 
respectively. Ligand binding leads to the receptor homodimerization and subsequent cross 
phosphorylation of specific cytoplasmic tyrosine residues, which act as binding sites for a plethora 
of signaling proteins involved in pivotal processes, such as cell proliferation, adhesion, motility, 
apoptosis, chemotaxis, and survival 21. The via activated by phosphorylation includes 
RAS/RAF/MEK, and PI3K/AKT/mTOR, and MAPK cascade 21,22 (Figure 4). 
  
 
Figure 4. Main pathways activated by the tyrosine-kinase receptor - KIT and its effects on carcinogenesis 22  
Figure from De Melo et al, 2012 
 
In KIT, different tyrosine residues including Tyr 568, Tyr 570, Tyr 703, Tyr 721, Tyr 730, Tyr 823,  
Tyr 900, and Tyr 936 may be phosphorylated. 
Phosphorylated tyrosines, and adjacent aminoacidic 
residues, form specific binding sites for downstream 
signaling molecules and promote activation of 
specific downstream signaling pathways (Figure 5) 
23. For example, it has been reported that Tyr 721 
acts as the docking site for the activation of PI3 
kinase and its downstream signaling pathway 
regulates cell survival and proliferation; Tyr 703 and 
Tyr 936 are docking sites for activation of Grb2 
protein, which is involved in activation of 
RAS/RAF/MEK/ERK signaling cascade 23.  
 
Figure 5. Schematic representation of the Tyr residues 
that may be phosphorylated and their interaction 
molecules 
Genetic alterations in KIT or PDGFRA genes involve two main regions, the receptor regulatory 
domains (dimerization region in the EC and JM domains) and the enzymatic domains (TK1 and 
TK2).
 The mutations characterizing GISTs are gain of function mutations and lead to a constitutive 
receptor activation, in a ligand-independent manner.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic representation of KIT exons 
harboring primary mutations in GISTs 
Approximately 80% of GISTs carry KIT 
pathogenic activating mutations, whereas 5% 
to 10% harbor activating mutations of the 
PDGFRA 24,25. Regarding KIT receptor, in 
GISTs the majority of mutations (~65%) 
involve the JM domain (exon 11) followed by 
mutations involving the EC dimerization 
domain (exon 9), retrieved in about 10% of 
cases. Primary KIT mutations can also involve  
exon 13 (TK1) and exon 17 (TK2), but these mutations are quite rare (~2%) (Figure 6) 26. 
With regard to PDGFRA, the most common PDGFRA mutation involves the exon 18 at codon 842 
(~5%), and leads to a substitution of an aspartic acid (D) with a valine (V) (D842V) 27, while 
mutations on exon 12 and 14 are less frequent 27. KIT and PDGFRA oncogenic alterations are 
mutually exclusive in GISTs and are driver events in GIST pathogenesis 28. 
1.4.1. Mutations in KIT gene 
 
Figure 7. Schematic representation of main mutations in KIT exon 11 
As mentioned before, the majority of 
mutations in KIT involve exon 11 and 
exon 9. Mutations can be aminoacid 
substitutions, in-frame deletions or 
insertions. With regard to exon 11, it has 
been observed that these kinds of 
alterations are associated with rupture of  
secondary structure of JM domain, leading to dimerization and receptor autophosporylation with 
consequent activation. The kinds of mutations occurring in this hot-spot are heterogeneous, 
including in-frame deletions of variable sizes, point mutations, deletions preceded by substitutions 
or a combination of these. The most common site of KIT mutations is in the 5’end of exon 11. In 
general, exon 11 deletions are associated with a more aggressive behavior if compared with the 
single aminoacid substitution; in particular, deletions affecting codons WK557–558 indicate a poor 
prognosis. Another hot spot, but less frequent, is located at the 3’ end of exon 11, that is 
characterized mostly by internal tandem duplication. GISTs with these type of mutations usually 
show a more indolent clinical evolution 29. Figure 7 shows the major mutations harbored in KIT 
exon 11 (K549 to W581) reported in COSMIC. It is possible to observe the wide heterogeneity in 
genetic alterations’ type. The main hot spots are aminoacids 557-558 and 559-560 30,31. With regard 
to exon 9, the most frequent mutation is represented by a duplication of six nucleotides (nts) 
encoding Ala-Tyr (at position 502–503) at the COOH terminus of the EC domain. Usually, GISTs 
harboring KIT exon 9 mutations have small bowel location and an aggressive clinical behavior 32. 
1.4.2. Mutations in PDGFRA gene 
GISTs with PDGFRA mutations represent a small subset; it has been previously reported that 
tumors with these specific alteration arise primarily in the stomach, mesentery and omentum 33. 
PDGFRA mutant GISTs have an epithelioid morphology, while spindle cells dominate the KIT 
mutant ones; in addition, up to 40% of these tumors are weak or negative for KIT expression in 
IHC. The mutational hot-spot in PDGFRA is codon 842 on exon 18, but other codons may be 
involved in aminoacid substitution or in-frame deletions and deletion/substitutions, as codon 845 to 
848. PDGFRA exon 18 mutations are believed to aberrantly stabilize the kinase activation loop 34. 
The principal difference with respect to KIT mutant GISTs is the location of primary mutations. 
Indeed, the majority of KIT mutations in GISTs arise in the JM domain (exon 11), but only ~10% of 
PDGFRA mutations are in this region (exon 12). On the contrary, mutations in the activation loop 
of KIT (exon 17) are rare events (<1%), but they are predominant in PDGFRA mutant GISTs (exon 
18) 33. The tumor genotype and specific type of KIT/PDGFRA mutation are important for the 
clinical outcome to TKIs and they will be discussed in the following paragraphs. 
1.5. KIT/PDGFRA wild-Type GISTs 
1.5.1. SDH-deficient GISTs  
 
About 10-15% of adult GISTs and 85% of the pediatrics do not present any alteration in KIT or 
PDGFRA genes and are referred to as KIT/PDGFRA wild-type (WT) GISTs. The major part of  
 
Figure 8. SDH deficiency promotes accumulation of oncometabolites, 
which leads to HIF1α-pathway activation 
these are associated with hereditary 
syndromes, including neurofibromatosis 
type 1 (NF1), Carney triad (CT), Carney-
Stratakis syndrome (CSS), and hereditary 
paraganglioma/pheocromocitoma 
(HPGL/PCC) syndrome. In the last years, 
substantial advances in knowledge of 
GISTs led to 
understand that KIT/PDGFRA WT GISTs are a heterogeneous group of different diseases 35. 
Indeed, it is well known that between 20-40% of all KIT/PDGFRA WT GISTs are succinate 
dehydrogenase complex (SDH)-deficient GISTs. SDH is a mitochondrial enzyme composed of four 
subunits, each of which encoded by four different genes SDHA, SDHB, SDHC, and SDHD 6. 
KIT/PDGFRA WT-(SDH)-deficient GISTs are recognized by IHC SDHB loss of expression, often 
due to germline and/or somatic loss of function mutations in any of the four SDH subunits. 
Frequently, SDH deficiency in tumor cells is due to a combination of a loss of function germline 
mutations in one of the SDH subunit genes and somatic loss of function mutations in the tumor 
cells, promoting inactivation of both alleles 36. Recently, several papers have reported that SDH 
inactivation may involve also epigenetic mechanisms as methylation of SDHC promotor 37. The 
SDH-complex takes part in the Krebs cycle and is responsible for conversion of succinate to 
fumarate. Therefore, SDH-deficient cells accumulate succinate, which promotes HIF1α 
overexpression and HIF translocation into nucleus. Overexpressed HIF proteins leads to aberrant 
transcription factors and to expression of hypoxia-associated tumorigenic responses and 
angiogenesis (Figure 8) 36. SDH-deficient GISTs are characterized by a peculiar gene expression 
signature that differs from the one observed in KIT/PDGFRA mutant GISTs; among the group of 
genes differentially expressed, one of the most important is the insulin-like growth factor 1 receptor 
(IGF1R), which is overexpressed in SDH-deficient GISTs but lost in KIT/PDGFRA mutant ones 
38,39. SDH-deficient GISTs show a number of clinically unique features such as young age, female 
gender predilection, gastric localization, mixed epithelioid and spindle cell morphology, diffuse 
KIT and DOG1 IHC positivity, frequent lymphnode metastatic involvement, and an indolent 
behavior 35,40. 
1.5.2. BRAF/RAS mutant GISTs 
Besides SDH-deficient, other subsets of KIT/PDGFRA WT GISTs have been characterized. Indeed, 
it has been reported that 5-13% of KIT/PDGFRA WT GISTs harbor a BRAF V600E mutation; 
BRAF is a pivotal intracellular protein kinase, involved in the RAS/RAF/MEK/ ERK signaling 
pathway. More than 90% of BRAF mutations occur in exon 15, resulting in the substitution of 
valine at codon 600 with a glutamic acid (V600E) 41. The V600E mutation increases BRAF activity 
due to creation of a salt bridge with K507. This interaction V600E - K507 mimics the 
conformational changes that happen during dimerization, and for this reason, BRAF V600E does 
not depend on dimerization for increased kinase activity 42. Usually, these BRAF mutant GISTs 
arise in the small intestine, in middle-aged females, and have a high mitotic rate and early 
metastasis 6,35,43. 
KRAS mutations in GISTs have a low frequency, spanning from ~1% to 11% of KIT/PDGFRA WT 
GISTs 41. These alterations may be present with KIT or PDGFRA mutations or as genetic event in 
KIT/PDGFRA WT GISTs 44,45. In a recent study from Hechtman et al. in 267 GISTs, one single 
KIT/PDGFRA WT GIST carried a KRAS mutation (p.G12V), which showed an aggressive behavior 
and resistance to multiple TKIs 46. 
1.5.3. NF1 mutant GISTs 
A hereditary condition leading to an 
increased incidence of GIST is an 
autosomal-dominant inherited disease 
referred to as NF1. NF1 is 
characterized by specific nerve, dermal 
and ocular manifestations, including 
café-au-lait spots, dermal 
neurofibromas and ocular 
manifestations, Lisch nodules, and 
optic glioma. 
  
Figure 9. The signaling pathway displays the oncogenic Ras signaling 
pathway as well as tumor suppressor NF1. 
 NF1 gene has more than 60 exons and represent one of the largest human genes; it encodes 
neurofibromin, a tumor suppressor that downregulates the RAS/RAF/MEK/ERK via (Figure 9). 
~7% of NF1 patients develop a GIST during their lifetime. GISTs arising in the setting of NF1 are 
SDHB positive and immunohistochemically positive for IGF1R expression 35,40. The majority of 
NF1-associated GISTs arise in the small intestine, with infrequent gastric exceptions. 
Morphologically, NF1-associated GISTs present spindle cells, are correlated with Cajal cell 
hyperplasia and associated with GI motility disorders 6. GISTs with mutations in BRAF/RAS or 
NF1 might be referred to as RAS-pathway (RAS-P) mutant GIST. 
1.5.4. Quadruple WT GISTs 
Recently, Pantaleo and coworkers, through massively parallel sequencing and gene expression 
analyses, reported for the first time the existence of an additional subset of KIT/PDGFRA WT 
GISTs 47. This subgroup has been named as quadruple WT (q-WT) because no genetic alterations 
in KIT/PDGFRA/SDH/RAS have been found. Transcriptome profile of this small group is deeply 
different from other GISTs, and q-WT GISTs could represent another unique group within the 
family of GISTs 35,47. To date, even if additional research groups have extensively worked on this 
new group of tumors, it has not been identified a common genetic driver event. On the contrary, a 
great molecular heterogeneity, with various and probably mutually exclusive mutational events, has 
been described 35. Figure 10 summarizes the majority of mutations retrieved in q-WT GISTs. 
 
Figure 10. q-WT GISTs are a heterogeneous family of tumors with different genetic events. 
Figure edited from Nannini et al, 2017 
 
However, given this pronounced molecular heterogeneity and besides the unquestionable GIST 
morphology, q-WT GISTs could represent a different disease than GISTs, deriving from a distinct 
population of ICCs. 
 1.6. Treatment of GISTs 
The standard chemotherapy is not effective in GISTs. However, until the introduction of TKIs at the 
beginning of 2000, doxorubicin and ifosfamide were used with low activity in GISTs compared to 
other soft tissue sarcomas, with a response rate < 5% 48. The median survival was approximately 9 
months 49. Today, GIST management for immunohistologically confirmed GISTs plans: i) surgical 
resection for resectable GISTs without metastasis; ii) administration of TKIs such as imatinib for 
unresectable, metastatic, or recurrent GISTs 9,50,51. The standard treatment for localized and 
resectable GISTs is the complete surgical resection of the lesion, with no tumor rupture. Indeed, 
tumor rupture is associated with a high risk of relapse and, for this reason, the laparascopic 
approach is discouraged for patients with large tumors. Ideally, the excision should have margins 
clear of tumor cells. GISTs sized up to 5 cm are managed through laparoscopic surgery which show 
terrific survival rates (92–96%) 1. Larger GISTs need open surgery and broad resections. Total 
gastrectomy may be needed for very large or multiple and recurrent GISTs including SDH-deficient 
GISTs in young patients. After surgical resection, the risk of relapse may be considerable, as 
defined by available risk classifications 52. 3 years of adjuvant treatment with imatinib (see below) 
is considered the standard approach for patients with a high risk of relapse. On the contrary, 
adjuvant therapy should not be considered when the risk is low, whereas decision-making should be 
discussed when the risk is intermediate 53. 
1.6.1. Imatinib mesylate 
In locally advanced inoperable and metastatic patients, imatinib is the standard treatment. Imatinib 
has been introduced in management of GIST at the beginning of 2000, led to a terrific improvement 
of prognosis of patients 5,54. 
Imatinib mesylate (formerly STI571, Gleevec® (United States) or Glivec® (Europe), Novartis) 
represents one of the most successful example of target therapy. In the late ‘80s, scientists at Ciba 
Geigy (now Novartis), started a project on the identification of compounds with inhibitory activity 
against protein kinases. The most promising molecule was STI571, which in vitro showed potent 
activity against all of the ABL tyrosine kinases, including ABL, viral ABL (v-ABL), and BCR-
ABL. In contrast, STI571 was inactive against serine/threonine kinases, did not inhibit the 
epidermal growth factor (EGF) receptor intracellular domain, and showed weak or no inhibition of 
the activity of the receptors for vascular endothelial growth factor (VEGFR-1 and VEGFR-2), 
fibroblast growth factor receptor 1 (FGFR-1), c-MET, and nonreceptor tyrosine kinases of the SRC 
family (FGR, LYN, and LCK). In 1998, a phase 1 trial with imatinib started in patients with chronic 
myeloid leukemia (CML), revolutionizing the treatment of this kind of blood tumor 55. Imatinib is a 
selective inhibitor, which binds competitively the ATP binding site of the target kinases including 
ABL, BCR-ABL, KIT, PDGFRA, PDGFRB, and receptor of macrophage-colony stimulating factor 
(CSF1R). This binding is due to the fact that imatinib mimics adenosine triphosphate (ATP) and 
can compete with ATP (Figure 11) 56. 
 
 
Figure 11. Mechanism of action of imatinib. A) Physiological conditions: 
ATP binds KIT or PDGFRA, promoting proliferation and survival. B) 
Imatinib binds the ATP structure and binds ATP binding pocket, preventing 
proliferation and survival. Figure edited by Rubin et al, 2007 
 
 
 
 In GIST cells, ATP binds to the active site of KIT or PDGFRA where it donates a phosphate to 
either KIT or PDGFRA, resulting in autoactivation, or to substrate molecules, resulting in activation 
of signal transduction. Imatinib, binding to the same site as ATP, prevents phosphorylation of 
downstream substrates and leads to inhibition of KIT or PDGFRA signaling 56. 
The first patient treated with imatinib in 2000 had a 
rapidly progressive metastatic GIST that was 
resistant to chemotherapy; after 4 weeks of imatinib 
treatment, the patient had a complete metabolic 
response and many of the liver metastases became 
hypodense (Figure 12) 57. The success in treating 
this patient quickly led to a multicenter trial which 
involved the Dana-Farber Cancer Institute, Fox-
Chase Cancer Center, Oregon Health & Science 
University Cancer Institute, and the University of  
 
Figure 12. PET Studies with [18F]Fluorodeoxyglucose. 
 A) Before STI571 therapy there were multiple metastases in 
the liver and upper abdomen. B) After four weeks of 
treatment, there was no abnormal uptake of tracer in the liver 
or right kidney 
Helsinki 5. In the trial, 147 adult patients, with a histologically confirmed, unresectable or metastatic 
GIST which expressed CD117, were enrolled. Patients were randomly treated either with 400 mg or 
600 mg of imatinib; the tumor response was evaluated after one month, three months, and six 
months, and every six months. No patient had a complete response, but ~54% of the patients had a 
partial response; in addition, ~28% of patients had stable disease, and disease progression was noted 
in 14% of patients within three months after study entry. In general, imatinib was well tolerated, 
with adverse effects from mild to moderate and similar to those reported in patients with CML 5. 
Similar results were observed in another phase I trial from the European Organization for Research 
and Treatment (EORTC). Based on the results from these two trials, imatinib was approved by the 
US Food and Drug Administration (FDA) for the treatment of unresectable and metastatic GIST on 
February 1st, 2002. Overall, imatinib achieved disease control in 70–85% of patients with KIT-
positive GIST, with a median progression free survival (PFS) of 20–24 months, and an estimated 
overall survival (OS) over 36 months 49. 
1.6.1.1 Correlation of kinase genotype and imatinib clinical outcome 
The first study investigating the correlation between the tumor genotype and imatinib clinical 
response dates back to 2003 58. In particular, Heinrich et al analyzed the tumor genotype and the 
clinical outcome of 127 patients enrolled onto a phase II trial of imatinib for metastatic GISTs 5, but 
a larger study involving 428 GIST cases was conducted later, in 2008, by the same authors 59. The 
results reported by the studies were concord, and showed that KIT exon 11 genotype had favorable 
impact on the imatinib response compared with GISTs with a KIT exon 9 mutation or WT 
genotypes. No significant difference in OS between patients whose tumors had a KIT exon 9 mutant 
or a WT genotype were observed 59. In addition, it was reported that patients with KIT exon 9 
mutant GISTs, who were treated with imatinib 800 mg, had a higher objective response rate 
compared with patients who were treated with imatinib 400 mg 59. With regard to PDGFRA 
mutations, GISTs with PDGFRA point mutations D842V showed a primary resistance to imatinib 
therapy, consistent with in vitro data 58.  
In general, according to the Clinical practice guidelines for GISTs released in 2018 by the European 
Society of Medical Oncology (ESMO), the standard dose of imatinib is 400 mg daily 9. However, 
data have shown that patients with tumors harboring the KIT exon 9 mutation have significantly 
better PFS on an 800 mg daily dose, which is considered the standard treatment in this subgroup. In 
metastatic GISTs, treatment with imatinib should be continued indefinitely, considering that 
stopping treatment is generally followed by relatively rapid tumor progression. 
1.6.1.2 Resistance to imatinib treatment 
As described below, ~80% of GISTs patients get benefits from imatinib treatment, however, after a 
median time of 24 months, a remarkable number of them become resistant 60. It has to be 
considered that KIT receptor may either be configured in an “open/on” conformation which allows 
ATP to bind or a “closed/off “ conformation which facilitates phosphorylation of substrates. 
Imatinib can bind KIT receptor only when it is in the open conformation and maintains the receptor 
in this state. The majority of KIT and PDGFRA mutations lead to the open conformation, thereby 
reducing the efficacy of imatinib 60. The term primary resistance is used to indicate patients 
showing progression within 3–6 months of initiating imatinib; approximately 15–20% of patients 
are primary resistant and most of the WT GISTs and PDGFRA D842V mutant patients display 
primary resistance 61. On the contrary, progression after more than 6 months of clinical response is 
defined as secondary or acquired resistance. Secondary mutations have only been found in patients 
with primary KIT mutations and rarely in those with primary PDGFRA mutations. Resistant 
mutations are most often found in the ATP-binding pocket of the kinase domain (exons 13 and 14) 
or in the kinase activation loop (exons 17 and 18) 61. Despite the acquisition of secondary 
mutations, mechanisms of delayed resistance may include: i) overexpression of KIT due to genomic 
amplification, (ii) loss of KIT expression with activation of an alternative tyrosine kinase, and (iii) 
ABC transporters overexpression, which may also represent a method for tumor cells to become 
resistant to TKIs.  
Therapeutic options for GIST patients progressed on imatinib consider dose escalation from 400 to 
800 mg /daily or switch to the second and third line TKIs. 
1.6.2. Sunitinib malate 
For those patients who progress under imatinib treatment or are intolerant to imatinib, sunitinib is 
the standard second line therapy, a second generation TKI 62. 
Sunitinib malate (formerly SU11248, Sutent®, Pfizer) is an oral oxindole multitarget kinase 
inhibitor, that inhibits specific tyrosine kinases including VEGFRs (types 1 and 2), PDGFRs 
(PDGFRA and PDGFRB), KIT, FMS-like tyrosine kinase-3 (FLT3), glial cell line derived 
neurotrophic factor receptor (RET) and CSF1R 63 (Figure 13). Similar to imatinib, sunitinib 
interacts with the adenosine triphosphate (ATP) binding pocket of these kinases and acts as a 
competitive inhibitor of ATP.  
 
 
Figure 13. Specific RTKs are blocked by sunitinib; sunitinib inhibition of signaling pathways 
PI3K/AKT/mTOR, MAPK, and PKC triggers different antitumor effects 64 
 
The inhibition of these RTKs blocks signal transduction, thereby affecting various cellular 
processes, including tumor growth and progression, angiogenesis, and metastasis 64. 
Besides the similarity with imatinib, sunitinib is effective in imatinib resistant GISTs, through 
unique binding characteristics and a broader spectrum of kinase inhibition. Primary and secondary 
mutations in the kinase powerfully influence sunitinib activity 65. For example, it has been reported 
that sunitinib showed higher clinical benefits and the objective response rates in patients with 
primary KIT exon 9 mutations with respect to GISTs with exon 11 mutations (clinical benefit rates: 
58% vs 34%; objective response rates: 37% vs 5%); moreover PFS and OS were significantly 
longer in KIT exon 9 mutant or KIT/PDGFRA WT patients compared to KIT exon 11 mutant ones 
65. With regard to KIT secondary mutations, in vitro and in vivo studies have shown that sunitinib is 
more effective against acquired mutations harbored in the ATP binding pocket, encoded by exon 13 
and 14, than those in the activation loop (KIT exon 17 or 18) 65. 
 1.6.3. Regorafenib 
After confirmed progression under sunitinib, a prospective placebo-controlled randomized trial 
showed that regorafenib can significantly prolong PFS. This treatment was approved as standard 
third line therapy for patients progressing on or failing to respond to imatinib and sunitinib, on 
February 25th, 2013 by FDA 66. Regorafenib (formerly BAY73-4506, Stivarga®, BAYER) is an 
orally available multikinase inhibitor with activity against multiple targets, including KIT, PDGFR, 
VEGFR-1 -2 -3, TIE2, RET, FGFR-1, RAF, and p38 mitogen-activated protein kinase (MAPK) 66. 
Many patients, after the development of resistance to imatinib and sunitinib, progress even under 
regorafenib. Currently, unfortunately there are no other therapeutic options and the rechallenge of 
imatinib or sunitinib may represent a reasonable option in advanced GIST patients after failure of 
previous treatments 67. Figure 14 summarizes the management of advanced/metastatic GISTs, 
according the guideline by ESMO released in 2018. 
 
 
Figure 14. Management of advanced/metastatic GISTs. aSurgery of limited progression may be considered. bIf previously treated 
with 400 mg imatinib. BSC: best supportive care; PD: progressive disease; PR: partial response; SD: stable disease 
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2. Pharmacogenetics and Epigenetics 
According to ACCR Cancer Progress report 2017 68, the number of global cancer-related deaths is 
arising, moving from 8.8 million in 2015 to 14.6 in 2035. This means that the impact of cancer will 
grow significantly in the next years if new and powerful tools for cancer prevention, detection and 
treatment will not be established or improved 68. Therefore, a better knowledge of cancer landscape 
and the identification of novel potential biomarkers is urgently needed. The development of new 
techniques, as high-throughput screening, has led to a better characterization of many diseases, 
including cancer; on the other side, it is became clear that genetic code by itself is not the only 
player in disease development, as well as in clinical response. Indeed, DNA sequence and genetic 
factors alone cannot fully explain all the processes implicated in diseases initiation and 
development; on the contrary, it is now well understood that additional factors are involved in the 
resulting phenotype. Epigenetic modifications are heritable changes and key actors at the basis of 
physiological growth and differentiation. The term ‘epigenetics’ was introduced in 1941 by Conrad 
Waddington to define a ‘branch of biology which studies the causal interactions between genes and 
their products, which bring the phenotype into being’. Epigenetic mechanisms are divided in three 
main groups: 
• DNA methylation, 
• histone modifications 
• non-coding RNAs (ncRNAs). 
DNA methylation promotes gene silencing, compacting chromatin or through modification of histones; 
indeed the CH3 group at CpG dinucleotides protrudes into the major groove of the double-stranded 
DNA, recruiting then proteins that favor those events.  
Histones may be altered by different modifications, including methylation, acetylation, phosphorylation, 
ubiquitination. These types of changes affect 15–30 aminoacid N-terminal histone tails impacting 
chromatin condensation.  
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ncRNAs are also considerably involved in post-transcriptional modifications. ncRNAs can affect the 
expression of specific target genes and therefor may interfere with the biological processes in which 
those genes have a role. This “RNA interference” can be mediated by exogenous RNA molecules, 
known as small interfering RNAs (siRNAs) or by endogenous RNA-microRNAs (miRNAs).  
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3. microRNA 
MicroRNAs (miRNAs) are a family of small non-coding RNAs (19–25 nucleotides -nts) that can 
regulate a plethora of biological processes via modulating expression of target genes at the post- 
transcriptional level 69.  
The first miRNA discovered, Lin-4, dates back to 1993 70. Lin-4 is involved in development of C. 
elegans, through regulation of expression of the protein lin-14 70. Subsequently, many evidences 
reported existence of a huge number of miRNAs in both invertebrates and vertebrates, and some of 
them are highly conserved; this suggested that modulation of gene expression via miRNAs is a 
general and important regulatory mechanism 69. Currently, according to Mirbase database, which is 
an archive of microRNA sequences and annotations, 48,885 mature miRNAs in 271 species are 
known, but, for most of them, function is unclear or unknown (updated to March 2018) 71. Calin 
and colleagues published the first data, showing an involvement of miRNAs in cancer, in 2002. 
They observed a deletion in B-cell chronic lymphocytic leukemia cells, which contains two miRNA 
genes, miR-15a and miR-16-1, and reported that the majority of clinical chronic lymphocytic 
leukemia cases have low expression level or deletion 72. miR-15a and miR-16-1 act as tumor 
suppressors and induce apoptosis through inhibiting Bcl-2, an anti-apoptotic protein overexpressed 
in malignant nondividing B-cells and in many solid malignancies 69. In the last two decades, the 
research has focused on miRNAs, characterizing their function and mechanism of action to finely 
regulate expression of target genes. Today, it is well known that miRNAs play a pivotal role in 
many processes, such as cell growth development, cell cycle, apoptosis and many others. 
Compelling evidences have established that miRNA expression is dysregulated in human diseases 
including cancer; miRNAs deregulation may take place via different mechanisms such as deletion 
or amplification of miRNA genes, abnormal transcriptional control of miRNAs, epigenetic 
modifications in the miRNA biogenesis machinery (Figure 15) 73.  
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Figure 15. MiRNAs as cancer players: examples of mechanisms, which can lead to 
deregulation of miRNAs. Figure from Calin AD et al, PNAS 2004 
 
MiRNAs may act as oncogenes or tumor suppressors and, depending on cellular context, a single 
miRNA may be both of them. Therefore, deregulation of miRNAs can affect the hallmarks of 
cancer, including sustaining proliferation, evading apoptosis and resisting cell death, promoting 
invasion and metastasis, and inducing angiogenesis.  
3.1. Biogenesis of miRNAs 
About 70% of miRNAs are located in introns and/or exons, and ~30% are located in intergenic 
regions 74. The biogenesis of miRNAs begins with their transcription by RNA polymerase II, or by 
RNA polymerase III, resulting in a primary transcript, referred to as pri-miRNA, which contains a 
33 bp hairpin stem, a terminal loop and a flanking single stranded sequence that can be 1-2 Kb in 
length 75,76. Pri-miRNA is then cleaved by Drosha bound by its regulatory subunit DGCR8, to 
liberate a hairpin structured precursor, or pre-miRNA, of ∼60–70 nts in the nucleus 77. 
The pre-miRNA from nucleus is then exported to the cytoplasm by Exportin5 (Exp5) associated 
with its Ran cofactor coupled to GTP. Once in the cytoplasm, Exp5 releases its pre-miRNA cargo; 
subsequently, the pre-miRNA is cleaved by Dicer to produce a miRNA duplex intermediate of ∼22-
24 nts. Argonaute (Ago) binds the duplex and incorporates the mature miRNA (single-stranded) 
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into the Ago-RNA complex, whereas the second strand - the passenger strand or miRNA* - is 
discarded 78,79. 
3.2. Mechanism of action 
A single miRNA can modulate the expression of hundreds of mRNA targets and a miRNA target 
may be regulated by multiple miRNAs. A miRNA binds its target through 6-8 nts, which constitute 
the so-called seed sequence, and usually the 5′ region of miRNA contributes more to the specificity 
and activity in binding targets. miRNAs regulate the target expression by base pairing to sequence 
motifs in the 3’UTR of mRNAs with perfect or imperfect complementarity 80. This imperfect base 
pairing makes miRNAs able to regulate the expression of multiple target genes, transcribed in the 
same cellular context as the miRNA. Besides this, it has been reported that miRNAs can bind even 
the 5’UTRs, but the evidence are less 81,82. Considering the binding between miRNAs and 3’UTRs, 
miRNAs control their target expression acting through two mechanisms. If the miRNA-mRNA 
base-pairing is perfect, the mRNA can be endonucleolytically cleaved and degraded; if the miRNA-
mRNA base-pairing is not perfect, there will be a block of translation. In both cases, the final result 
is a down-regulation of expression at the protein level 83.  
3.3. miRNAs and cancer 
The first indication that miRNAs are key player in human disease dates back to 2002, when Calin 
and colleagues showed that miR-15a/16-1 cluster is frequently deleted in chronic lymphocytic 
leukemia, implicating these miRNAs as tumor suppressors 72. After that finding, a huge number of 
reports were published.  
All the tumors analyzed have reported a specific miRNA signature, “miRNome”, which is peculiar 
for tumor tissue and is often associated with clinico-pathological features of the tumors. In general, 
it has been observed that most miRNAs are down-regulated in cancers with respect to the normal 
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tissue counterparts, as indication of the general loss of differentiation of tumor cells. This is in 
agreement with studies in vivo, which showed that a global depletion of miRNAs by genetic 
deletion of the miRNA-processing machinery favorites cell transformation and tumorigenesis 84 85. 
This suggests that miRNAs deregulation is not a consequence of tumorigenesis but, rather, it has a 
causative role in cancer development. Beside a general down-regulation of miRNAs in cancers, 
diverse miRNAs are up-regulated, and have an oncogenic roles 86. In general, as previous 
mentioned, a single miRNA, depending on the cellular context, may have a dual role and be a tumor 
suppressor or an onco-miR. For example, miR-221 and miR-222 are important in GIST because 
target the driver oncogene, KIT, and, as a consequence, they function as tumor suppressors 87. 
However, in other solid tumors, including glioblastoma, prostate, and breast cancer, they also target 
important tumor suppressors - as PTEN, p27, p57 and TIMP3 - and function as oncogenic miRNAs 
by suppressing these tumor suppressors  
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4. Aim 
GISTs are rare soft tissue sarcomas, which, however, represents the most common mesenchymal 
tumor of gastro intestinal tract. GISTs are considered a worldwide paradigm of molecular biology 
in solid tumors 89. With the application of high throughput technologies into basic and translational 
research, molecular biology of GISTs has been progressively deepened and the GIST paradigm has 
been proven to be more complex than expected, due to an extensive molecular heterogeneity within 
all GIST tumors, and the identification of different subsets often characterized by peculiar genotype 
and phenotype 90. Besides the importance of genomic alterations, epigenetics, including miRNA 
and methylation deregulation, could be a key player in driving tumorigenesis, as well as in clinical 
response and drug resistance. To date, it is well established that KIT/PDGFRA mutant and 
KIT/PDGFRA WT GIST patients are deeply different at both pathogenesis and molecular level. 
However, reports regarding miRNAs expression in GISTs are still a small number and often do not 
take into account tumor genotype and GIST molecular heterogeneity. For the above mentioned 
reasons, to identify novel potential biomarkers of GIST pathogenesis, I) the first aim of the PhD 
project was to investigate and characterize the differences in miRNAs expression levels, comparing 
KIT/PDGFRA mutant and KIT/PDGFRA WT GISTs.  
II) Secondly, we aimed to characterize novel mechanisms of pharmacological resistance to a 
PI3KCA inhibitor in trial at Sant’Orsola Malpighi Hospital for GIST patients who previously failed 
imatinib and sunitinib. Indeed, all the treatment lines so far approved in GISTs are TKIs showing a 
similar mechanism of action, but the majority of patients experience disease progression. Therefore, 
it is extremely important to identify alternative therapeutic options with different mechanisms. 
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5. Fist aim: identification of potential novel biomarkers correlated 
with GIST pathogenesis  
As already previously mentioned, little is known about differences in miRNA expression between 
KIT/PDGFRA mutant and KIT/PDGFRA WT GIST. In view of these considerations, we integrated 
multiple expression profiles of miRNA and mRNA to construct a miRNA-mRNA regulatory 
network in KIT/PDGFRA WT GIST patients. Subsequently we performed a series of functional in 
vitro studies to deepen the potential epigenetic network.  
Part of the data reported below are reproduced from Epigenomics. 2016 Oct;8(10):1347-1366, with 
permission of Future Medicine Ltd.  
5.1. Materials and Methods 
Patients - To identify a miRNAs signature in GISTs, we profiled the expression of a cohort of GIST 
patients - discovery set - which included 9 KIT/PDGFRA mutant and 4 KIT/PDGFRA WT cases. A 
second cohort of patients, designed as validation set, was recruited to validate the capacity of 
specific miRNA to discriminate between KIT/PDGFRA mutants and KIT/PDGFRA WT disease. In 
the KIT/PDGFRA WT group, the SDH-deficient status was assessed by both IHC negativity for 
SDHB protein and genome sequencing of all four SDH subunits. The validation set consisted of 27 
GISTs, of which 16 were not overlapping with the discovery cohort and included 7 KIT/PDGFRA 
WT and 20 KIT/PDGFRA mutant GIST cases (13 KIT/PDGFRA mutant and 3 KIT/PDGFRA WT 
cases not overlapping with the discovery set) (reproduced from Epigenomics, 2016 Oct;8(10):1347-
1366). Subsequently, we were able to expand the validation set from 27 to 37 GIST cases (referred 
to as validation set II). The miRNAs, which maintained the statistical significance in the validation 
set, were finally tested in the validation set II. 
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RNA extraction - Total RNA (including miRNAs) was extracted from liquid nitrogen snap-frozen 
tumor samples using Qiagen miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to 
manufacturer’s instructions. 
Genome-wide miRNA expression profiling - miRNAs expression was investigated using the Agilent 
Human miRNA microarray v.2 (#G4470B, Agilent Technologies, CA, USA). This microarray 
consists of 60-mer DNA probes synthesized in situ and contains 15,000 features, which represent 
723 human miRNAs, sourced from the Sanger miRBase database (Release 10.1). Microarray results 
were analyzed by using the GeneSpring GX v.12 software (Agilent Technologies). Data 
transformation was applied to set all the negative raw values at 1.0, followed by a quantile 
normalization and a log2 transformation. Filters on gene expression were used to keep only the 
miRNAs expressed in at least one sample. Then, samples were grouped according to the presence or 
not KIT/PDGFRA mutations. Differentially expressed miRNAs were identified by a 2 fold-change 
filter followed by a moderated t-test, with p<0.05 by means of a moderated t-test with Benjamini-
Hochberg correction. A principal component analysis (PCA) was applied to compress the 
multidimensional miRNAs expression data to three dimensions while maintaining the variance. The 
data have been submitted to Gene Expression Omnibus - GEO - (Entry series number: Submitted E-
MTAB-4490) following the requirements of minimum information about a microarray experiment 
(MIAME).  
Gene expression - Quality-controlled RNA was labeled according to Affimetrix expression 
technical manual before hybridization to HGU133 Plus 2.0 array following manufacturer’s 
instruction. Gene expression data were quantified by the robust multi-array analysis (rma) 
algorithm. Unsupervised analyses were applied to a subset of genes whose standard deviation varied 
at least of 0.5. For hierarchical agglomerative clustering, Pearson’s correlation coefficient and 
average linkage were respectively used as distance and linkage methods in DNA-Chip Analyzer 
(dChip) software. Differentially expressed genes were selected through supervised techniques using 
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SAM (Significance Analysis of Microarrays) package in R, with a two class unpaired 
(KIT/PDGFRA WT and mutated samples) T-statistic and permutated 1,000 times. Only genes with 
0% q-value cut-off level were considered to be differentially expressed and selected for subsequent 
analysis. The data have been submitted to GEO (Entry series number: GSE20708), following the 
requirements of minimum information about a microarray experiment (MIAME). 
Identification of validated mRNA/miRNA targets - The validated targets were obtained from the 
miRTarBase database (http://microrna.sanger.ac.uk/) that contains miRNA–target interactions 
(MTIs) with experimental support (2DGE, immunoprecipitation, Luciferase reporter assay, Mass 
spectrometry, Microarray, qRT-PCR, Western blot, Next Generation Sequencing (NGS), ELISA, 
IHC. Using these information, miRNA and mRNA arrays were analyzed to highlight pairs of 
mRNA/miRNA that were discordant (UP vs DOWN and viceversa). Potential miRNA-mRNA 
interactions and miRNA/mRNA expression profiles were used to construct functional interaction 
networks using Ingenuity Pathway Analysis (IPA, Ingenuity Systems, CA, USA). 
Functional annotation, GO and pathway analysis - IPA was performed to identify the molecular 
pathways and functional groupings. Gene interaction networks, bio-functions and pathway analysis 
were generated using differentially expressed genes (DEGs) into known functions, pathways, and 
networks primarily based on human and rodent studies. The DEGs were organized in Gene 
Ontology Bio-Functions and Regulatory Effect Networks available from the Ingenuity database. 
The significance was set at a p-value of 0.05. IPA pathway explorer and miRNA/mRNA 
interactions were used to find a link between deregulated genes and deregulated miRNAs in array 
experiments. 
Validation of miRNA array - miRNA array expression profiles of selected miRNAs were evaluated 
by TaqMan miRNAs assays (Applied Biosystems, CA, USA), and RNU48 and RNU44 were used 
as internal normalizer reference. The analysis was conducted according to standard TaqMan 
miRNAs assay protocol and run on a 7900 HT Fast Real-Time PCR System (Applied Biosystems). 
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Each sample was analysed in triplicate. Quantitative analysis was performed by the ΔΔCt method. 
The miRNAs chosen for validation included the top up- and down- regulated miRNA; furthermore, 
we selected miRNAs whose expression differed significantly and target genes known to be 
interesting for GISTs and novel genes for GISTs as well. 
Western blotting - IGF1R, CD44 and CDK6 expressions were analyzed in 7 KIT/PDGFRA WT-
SDH-deficient and 11 KIT/PDGFRA mutant cases. Frozen tumor samples were diced in ice-cold 
lysis buffer (1% NP40, 50 mM Tris-HCl, pH 8.0, 100 mM sodium fluoride, 30 mM sodium 
pyrophosphate, 2 mM sodium molybdate, 5 mM EDTA, 2 mM sodium orthovanadate) on dry ice 
and homogenized; the cell lysate was then rocked overnight at 4°C. Lysates were cleared by 
centrifugation at 14,000 rpm for 30 min at 4°C, and lysate protein concentrations were determined 
using a Bradford method (Bio-Rad, CA, USA). Lysates were separated by gel electrophoresis using 
NuPAGE® 4–12% Bis-Tris gels (Invitrogen–Thermo Fisher Scientific, MA, USA) and blotted to 
nitrocellulose membranes. The hybridization signals were detected by chemiluminescence (ECL, 
Invitrogen, Thermo Fisher Scientific) and captured using ChemiDOC (Bio-Rad). Primary 
antibodies were IGF1R (Cell Signaling Technology,Inc., MA, USA; #3027), CDK6 (clone 8H4, 
Sigma-Aldrich, MO, USA), CD44 (Sigma-Aldrich) and β-actin (clone AC15, Sigma-Aldrich). 
Cell cultures - GIST48 and GIST882 cell lines were kindly provided by Dr Fletcher (Brigham and 
Women's Hospital, Harvard Medical School, Boston, MA, USA). GIST48 was established from a 
patient that had progressed - after an initial clinical response - during imatinib therapy; this cell line 
is characterized by a primary, homozygous KIT exon 11 mutation (p.V560D) and a secondary, 
heterozygous KIT exon 17 mutation (p.D820A). Cells were cultured in IMDM (Gibco, Thermo 
Fisher Scientific), supplemented with 15% fetal bovine serum (FBS) and 1 mM L-Glutamine 
(Invitrogen). GIST882 was established from an untreated, human primary tumor harboring a 
homozygous imatinib sensitive mutation in KIT exon 13 (p.K642E). Cells were maintained in 
RPMI-1640 (Gibco), supplemented with 15% FBS and 1 mM L-Glu (Invitrogen). All experiments 
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were performed in newly thawed cell lines. GIST lines were routinely monitored by Sanger 
sequencing to confirm their KIT mutational status and to exclude additional secondary mutations in 
KIT. 
Luciferase assay - The pMirNanoGlo dual-Luciferase vector, containing both the Renilla luciferase 
gene and the Firefly luciferase gene, was 
purchased from Promega (Promega, Madison, 
WI, USA) (Figure 16). pMirNanoGlo, 
containing a 2,051 bp IGF1R 3’UTR region, 
was generated as follow. The IGF1R 3’UTR 
region, containing all the miR-139-5p 
(positions 2,486-2,493 and 3,742-3,748) and  
 
miR-455-5p (position 3782-3788 and 4198-4204) binding sites, was amplified from human 
genomic DNA, introducing the NheI and XhoI restriction sites (Figure 17). First, this amplicon was 
cloned into a pGEM® vector using the pGEM-T Easy Vector Systems (Promega) according to the 
manufacturer’s instructions. The amplified DNA fragments was then subcloned into the 
pMirNanoGlo vector, downstream of the Renilla luciferase stop coding region. All constructs were 
sequence-verified prior to be used. Primers are reported in table 1.  
Table 1: List of primers  
Primer Sequence Tmelting Aim 
IGF1R 2051 fwd AGGCTAGCAGGAGTAAGAACAAAGCTGGGA 58°C PCR 
IGF1R 2051 rev ATCTCGAGTGGGGTGGTCTGGGTCTT 58°C PCR 
IGF1R 2051 fwd CGGCTTTTTTGCTGGTCA 43°C Sanger  
IGF1R 2051 rev GCGTGGATGAGGTTACCAG 48°C Sanger 
IGF1R 2051 fwd GGCAATTCCAGCCTAAGTGA 47°C Sanger 
IGF1R 2051 rev CAGTACACACCAGCTCCTGCT 51°C Sanger 
Figure 16. Circular plasmid map of pMirNanoGlo 
5. Aim I 
________________________________________________________________________________ 
 
 
Figure 17. IGF1R 3’UTR cloned in pGEM and pMiRNanoGlo. In red are highlighted primers used to amplify, whereas in blue are 
highlighted primers used to sequence the amplicon 
 
GIST882 and GIST48 cells were transfected using Amaxa Nucleofector II device (Lonza AG, 
Switzerland). In brief, 1×106 cells were resuspended in 100 μl Ingenio Electroporation solution 
(Mirus Bio, LLC; WI, USA) and mixed with 100 pmol of miRNA mimic (Mirvana miRNA mimic, 
Ambion, Thermo Fisher Scientific). Cells were then electroporated using the program T-20, and 
seeded in triplicate in a 96 wells plate. After 24h, Firefly and Renilla luciferase activities were 
quantified using the Dual luciferase system (Promega) through an EnSpire Multimode Plate Reader 
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(Perkin Elmer, Inc, MA USA). Renilla luciferase expression was normalized on the Firefly 
luciferase expression. Independent triplicate experiments were performed for each plasmid 
construct. 
Site-Directed Mutagenesis - To evaluate the contribution of each of the two binding sites, we 
generated different constructs in which we individually deleted the seed sequences. To do that, we 
used the Phusion Site-Directed Mutagenesis Kit (Thermo Fisher Scientific); deletions were created 
by designing primers that border the deleted area on both sides (see figure 18 for a schematic 
presentation).  
 
Figure 18. The Phusion Site-Directed Mutagenesis protocol 
Transient transfection - Anti-miR-139-5p and anti-miR-455-5p were purchased from Ambion. 
Anti-miR-139-5p: UCUACAGUGCACGUGUCUCCAGU (#AM11749), anti-miR-455-5p: 
UAUGUGCCUUUGGACUACAUCG (#AM10529).  
Anti-miR-139-5p and anti-miR-455-5p were transfected in GIST48 and GIST882 using RNAiMAX 
Lipofectamine (Invitrogen). A random miRNAs inhibitor pool was used as negative control. The 
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miRVANA microRNA inhibitors are single-stranded, chemically enhanced oligonucleotides 
designed to inhibit the endogenous miRNAs. Cells were transfected with 100 nM of the indicated 
oligonucleotide and we evaluated cell migration, apoptosis, cell cycle and proteins’ expression. 
Analysis of apoptosis - Apoptosis was assayed using the Guava Nexin kit (4500-0450, Merck 
Millipore, MA, USA) and the Guava PCA system (Guava Technologies, CA; USA). Cells were 
harvested 24 and 48 h after transfection treatment. Cells were then plated into a round bottom 96 
well plate in triplicate, treated with 100 µl of Guava Nexin reagent according to the manufacturer’s 
protocol, and incubated at room temperature for 20 min in dark. Samples were then analyzed using 
the Guava PCA system. 
Cell migration assay - Migration of GIST cells treated with 100 nM miR inhibitor was investigated 
using Radius™ 24-Wells Cell Migration Assay (Cell Biolabs, CA, USA). In particular, 3x105 cells 
were plated 24h before treatment. Then, cells were treated with 100 nM of anti-miR-139-5p/455-5p 
and were left to grow out until up to 96h and pictures were taken every 24 hours to monitor the cells 
migration. 
Invasion assay - Invasion of GIST cells treated with miR inhibitor at 100 nM was investigated 
using CytoSelect™ 24-Wells Cell Migration and Invasion Assay (8 µm, Colorimetric Format) (Cell 
Biolabs). Cell suspensions containing 1x106 cells/ml in serum free media were prepared (treated or 
not); 500 µL of media containing 10% FBS was added in the lower well of the migration plate. 
Then, 300 µL of the cell suspension solution was added to the inside of each insert and incubated 24 
hours at 37°C. After that, the small chamber were collected and fixed by Cell Stain Solution. Each 
insert was then washed with 200 µL of Extraction Solution per well, then incubated 10 mins on an 
orbital shaker. Finally, 100 µL were transferred from each sample to a 96-wells plate and OD 560 
nm measured. 
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5.2. Results 
Differential miRNAs expression between KIT/PDGFRA mutant GISTs vs KIT/PDGFRA WT GISTs– 
miRNA profiling - The 3D PCA plot, distributing the samples into three dimensional space based on 
variance in miRNAs expression, clearly indicates that KIT/PDGFRA WT SDH-deficient GISTs 
(denoted thereafter as KIT/PDGFRA WT GISTs) clustered together in a distinctive pattern 
compared to mutant GISTs (Figure 19A). The array highlighted a total of 56 deregulated miRNAs 
out of the 723 analyzed (Figure 19B).  
 
Figure 19. A) PCA of the miRNA profile in KIT/PDGFRA mutant GISTs (M) compared to KIT/PDGFRA WT GISTs (WT). Red dot 
represent WT GISTs, while black ones represent KIT mutant (small) and PDGFRA mutant GIST (big). B) miRNAs modulated in 
KIT/PDGFRA mutant GISTs compared to KIT/PDGFRA WT GISTs. Volcano plot depicting the 56 statistically significant (fold 
change ≥ 2 and a P < 0.05) deregulated miRNAs (red plot) in KIT/PDGFRA mutant GISTs compared to WT GISTs. The gray plot 
represent miRNAs with no significant expression changes 
 
In particular, the expression of 16 miRNAs was up-regulated and 40 miRNAs were down-regulated 
in KIT/PDGFRA mutant GISTs compared to KIT/PDGFRA WT GISTs. All the differentially 
expressed miRNAs are reported in Table 2.  
Table 2. miRNAs found to be significantly deregulated in KIT/PDGFRA mutant GISTs 
compared to KIT/PDGFRA WT GISTs. 
miRNA name Regulation 
Absolute  
Fold change 
Corrected 
 P-value 
hsa-miR-330-3p Up-regulated 13,47 0,0019 
hsa-miR-886-3p Up-regulated 11,49 0,0034 
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hsa-miR-455-5p Up-regulated 8,88 0,0061 
hsa-miR-455-3p Up-regulated 9,15 0,0077 
has-let-7b Up-regulated 2,37 0,0099 
hsa-miR-335* Up-regulated 9,26 0,018 
hsa-miR-139-5p Up-regulated 6,28 0,019 
hsa-miR-148° Up-regulated 5,80 0,019 
hsa-miR-193b* Up-regulated 4,54 0,019 
hsa-miR-193b Up-regulated 2,82 0,019 
has-let-7c Up-regulated 2,03 0,020 
hsa-miR-497* Up-regulated 3,29 0,033 
hsa-miR-152 Up-regulated 3,02 0,033 
hsa-miR-195* Up-regulated 5,38 0,034 
hsa-miR-199b-5p Up-regulated 8,32 0,038 
hsa-miR-487b Up-regulated 11,76 0,045 
hsa-miR-129-1-3p # Down-regulated 11,13 5,12 x 10-8 
has-miR-491-5p Down-regulated 4,16 0,0011 
has-miR-129-5p Down-regulated 67,11 0,0018 
has-miR-450a Down-regulated 18,54 0,0041 
hsa-miR-424 Down-regulated 7,16 0,0082 
hsa-miR-214* Down-regulated 2,96 0,0086 
hsa-miR-151-3p Down-regulated 2,24 0,0086 
has-miR-876-5p Down-regulated 8,24 0,0099 
hsa-miR-542-3p Down-regulated 19,97 0,013 
hsa-miR-584 Down-regulated 5,66 0,013 
hsa-miR-328 Down-regulated 2,90 0,013 
hsa-miR-769-5p Down-regulated 2,57 0,013 
hsa-miR-129-2-3p § Down-regulated 87,08 0,015 
hsa-miR-542-5p Down-regulated 20,57 0,016 
hsa-miR-590-5p Down-regulated 2,27 0,017 
hsa-miR-876-3p Down-regulated 5,63 0,019 
hsa-miR-34b* Down-regulated 3,57 0,019 
hsa-miR-326 Down-regulated 3,22 0,019 
hsa-miR-1237 Down-regulated 2,57 0,019 
hsa-miR-214 Down-regulated 2,55 0,019 
hsa-miR-374b Down-regulated 2,39 0,019 
hsa-miR-30e* Down-regulated 2,05 0,019 
hsa-miR-199a-5p Down-regulated 2,03 0,019 
hsa-miR-338-3p Down-regulated 7,18 0,020 
hsa-miR-933 Down-regulated 2,81 0,021 
hsa-miR-186 Down-regulated 3,53 0,026 
hsa-miR-28-5p Down-regulated 2,11 0,027 
hsa-miR-873 Down-regulated 24,66 0,033 
hsa-miR-361-3p Down-regulated 2,36 0,033 
hsa-miR-1225-3p Down-regulated 2,05 0,033 
hsa-miR-191* Down-regulated 2,08 0,034 
hsa-miR-34a Down-regulated 2,37 0,036 
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hsa-miR-551b Down-regulated 28,58 0,041 
hsa-miR-490-5p Down-regulated 2,56 0,041 
hsa-miR-197 Down-regulated 2,27 0,041 
hsa-miR-425* Down-regulated 2,06 0,041 
hsa-miR-101* Down-regulated 3,11 0,044 
hsa-miR-490-3p Down-regulated 4,62 0,045 
hsa-miR-30c-1* Down-regulated 2,41 0,050 
hsa-miR-15a Down-regulated 2,18 0,050 
Previously: # hsa-miR-129*; § has-miR-129-3p 
In Italic are highlighted miRNA selected for validation. 
 
Hierarchical clustering of all samples separated KIT/PDGFRA mutant GIST and KIT/PDGFRA WT 
GISTs into two distinct clusters (Figure 20), confirming the prior PCA results. 
 
Figure 20. miRNA hierarchical clustering. The miRNAs identified as differentially expressed between KIT/PDGFRA mutant GISTs 
and KIT/PDGFRA WT GISTs were selected as markers for unsupervised hierarchical clustering. 
 
Different mRNA expression between KIT/PDGFRA mutant GISTs vs KIT/PDGFRA WT GISTs – 
mRNA profiling - A comparative analysis between KIT/PDGFRA mutant GISTs vs KIT/PDGFRA 
WT GISTs revealed 235 differentially expressed genes with a false discovery rate of 0. In particular 
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123 genes were down-regulated (fold range: -0.7 to -5.5; Table 3) while 112 genes were up-
regulated (fold range: 0.98 to 7.10; Table 3) (Figure 21A). 
Table 3. The most deregulated mRNAs in KIT/PDGFRA mutant 
GISTs compared to WT GISTs. 
Down-expression  Over-expression 
Gene 
fold 
change   Gene 
fold 
change 
FBXL16 -5,058  SCG5 7,163 
IGF1R -4,934  LY6H 5,969 
42074 -4,864  PRTFDC1 5,320 
CRLF1 -4,418  TNFRSF19 5,043 
LHX2 -4,099  FAM19A1 4,996 
ASRGL1 -4,00  KCNT2 4,722 
DNER -3,936  IGDCC4 4,675 
KIRREL3 -3,927  CFH 4,389 
FGF4 -3,829  NIPAL2 4,300 
GRIA1 -3,700  TSPYL5 4,285 
CBLN2 -3,641  PIK3CG 4,213 
FAM84B -3,565  SPATA18 4,125 
PPP2R2B -3,485  PLBD1 4,050 
CYP3A7 -3,462  RBP1 4,010 
CDH2 -3,399  TMEM150C 3,944 
CXADR -3,376  DNAJC15 3,898 
DPYSL4 -3,335  ME1 3,886 
ISM1 -3,277  PDZD2 3,872 
GLRB -3,252  RHOBTB3 3,730 
ELAVL3 -3,081  BASP1 3,707 
PHLDA2 -3,041  CEP41 3,691 
FOXO6 -3,035  SLC2A10 3,637 
ADAMTS19 -2,952  ACKR3 3,628 
ZNF804A -2,926  KCNE4 3,498 
MBNL1-AS1 -2,838  PTPLAD2 3,458 
SV2C -2,812  SERPINB9 3,423 
BMP8B -2,809  PLA2G16 3,415 
ADARB1 -2,750  SERP2 3,413 
COLGALT2 -2,699  LOC728613 3,400 
C1orf145 -2,684  SOCS2 3,400 
KCND3 -2,611  IQCA1 3,387 
EFNA2 -2,589  CPQ 3,353 
ERBB3 -2,588  PTER 3,292 
NPNT -2,535  SQRDL 3,253 
PRDM16 -2,533  C16orf89 3,251 
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DAPK1 -2,435  IL1R1 3,240 
EVA1A -2,433  CLIC2 3,211 
TBX21 -2,429  EPHX2 3,152 
CD44 -2,401  CAPS2 3,105 
NRCAM -2,390  ALDH7A1 3,048 
PDE4DIP -2,383  FBXO4 3,046 
P4HA3 -2,382  MINA 3,045 
ARSB -2,343  C9orf64 3,042 
GPD2 -2,309  SERPINB1 3,023 
SLC1A1 -2,276  TMEM173 3,020 
FAM46C -2,249  CPNE8 3,006 
TAPBPL -2,236  CYSLTR1 3,004 
TMEFF1 -2,227  ZNF423 2,977 
FAM43A -2,226  RANGRF 2,932 
KIF21B -2,224  COX7A1 2,926 
DAAM1 -2,217  GPX7 2,895 
EFR3B -2,213  C8orf88 2,861 
USP53 -2,206  PARVA 2,854 
TMEM59L -2,179  WWTR1 2,846 
ARX -2,111  CREB3L1 2,773 
MAGI2-AS3 -2,103  PLIN2 2,715 
SLC4A7 -2,081  MCTP2 2,714 
TARBP1 -2,070  SLC9A9 2,683 
RIMBP2 -2,050  PDLIM4 2,681 
TESK2 -2,012  S100A13 2,665 
PHKA1 -2,009  CHCHD10 2,661 
LSR -2,005  TP73-AS1 2,622 
FGFBP3 -1,994  PHLDA1 2,568 
LRCH2 -1,869  HTATIP2 2,544 
42066 -1,866  ZNF22 2,509 
NRG3 -1,843  FMOD 2,484 
42068 -1,841  FAM213A 2,464 
FAM3C -1,788  SELENBP1 2,417 
CDH23 -1,787  LOC728819 2,416 
TMEM30A -1,783  CDIP1 2,365 
PPM1B -1,762  FAM50B 2,357 
ARHGAP5 -1,740  MXRA7 2,333 
DNAH12 -1,720  RNF135 2,332 
DDAH1 -1,711  IMPACT 2,269 
ENAM -1,640  GYPC 2,199 
DNAJB4 -1,627  CD40 2,106 
TTLL7 -1,614  PBX3 2,067 
EGFL7 -1,606  GLRX 2,066 
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NPC2 -1,597  DENND1B 2,020 
MPP5 -1,580  CYB561 2,005 
USP33 -1,530  NPEPL1 2,002 
HEXA -1,520  SETD9 2,000 
SPPL2A -1,506  TMEM220 1,997 
ARRB1 -1,478  ZNF239 1,984 
GPR63 -1,448  MAPK10 1,983 
TMEM74B -1,414  OCIAD2 1,975 
SLC25A48 -1,411  PHF19 1,970 
GALT -1,405  GSE1 1,968 
C1orf21 -1,384  ZNF621 1,964 
ST7 -1,339  N6AMT2 1,963 
EPN2 -1,338  CYP27A1 1,894 
TMEM14C -1,323  RHOD 1,889 
PATZ1 -1,267  TTC12 1,888 
GRN -1,250  ACAA2 1,881 
NDUFAF4 -1,241  LOC730102 1,855 
NT5E -1,236  C8orf48 1,854 
NENF -1,221  CLMP 1,786 
SPEF2 -1,210  LOC100049716 1,757 
ERP29 -1,206  EPHX1 1,750 
DENND2C -1,188  RFESD 1,710 
CPEB3 -1,179  MYD88 1,707 
ATP6V1D -1,162  LOC101927027 1,691 
RECK -1,160  ENKD1 1,677 
SIRT2 -1,159  DDB2 1,665 
MBNL1 -1,126  MAP1LC3A 1,611 
AKT3 -1,095  CTSF 1,5717 
EFNA3 -1,075  HAUS7 1,530 
ECI2 -1,060  PRR5 1,424 
TMEM14B -1,060  PPM1M 1,370 
PTP4A1 -1,033  VILL 1,316 
NCSTN -1,025  TPST1 1,094 
HAGHL -1,023  ATG12 0,981 
SIPA1L1 -1,004     
LUZP1 -0,999     
ABL2 -0,991     
ZFYVE1 -0,991     
KIAA1522 -0,950     
SMARCD3 -0,846     
ELFN1 -0,824     
CPNE9 -0,760     
APC2 -0,758     
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RIMBP3 -0,735     
SDCBP2-AS1 -0,734       
False discovery rate=0 
 
In the figure 21B the most deregulated genes are summarized. Several markers were validated by 
qRT-PCR and previously reported 91. The validated genes, which included IGF1R, LHX2, and 
KIRREL3, confirmed a good correlation with the differential expression observed in the array. 
 
Figure 21. A) mRNA hierarchical clustering. The mRNA identified as differentially expressed between KIT/PDGFRA mutant 
GISTs and KIT/PDGFRA WT GISTs were selected as markers for unsupervised hierarchical clustering. B) The top scored 
deregulated genes. 
 
Differentially expressed genes between KIT/PDGFRA mutant GISTs vs KIT/PDGFRA WT GISTs - 
bioinformatics analysis - All genes transcripts underwent GO term classification, which included 
Biological Process, Cellular Component and Molecular Function, and gene term enrichment 
analysis. Results showed a significant clustering of these differentially expressed genes. Genes were 
mainly involved in developmental processes and, to a less extent, in metabolic and cellular 
processes (Figure 22). 
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Figure 22. GO functional enrichment analysis of up- and down-regulated genes. 
 
miRNA and mRNA arrays correlation - To construct miRNA-DEGs networks, we downloaded the 
experimentally verified associations between human miRNAs and their targets from miRTarBase, 
which has accumulated more than 400,000 miRNA-target interactions, collected by manually 
surveying pertinent literature after systematic data mining of the text. This dataset contained 
miRNA-target interactions consisting of 963 miRNAs and 12,518 mRNAs. The results are reported 
in table 4. Among 56 deregulated miRNAs retrieved by our data, 44 had verified associations with 
their targets. Among the targets with an inverse expression compared to the miRNA expression, we 
were able to identify 17 mRNA-miRNA networks (Table 4). miRNA validation - Among the 44 
miRNAs, 29 were validated in the validation set. In addition, to avoid missing significant results, 
we predict the miRNA targets using different in silico software, including miRTarBase, DianaLab, 
MiRDB, microRNA.org, PicTAR, PITA, MiRanda, and a target had to be predicted by at least 5 
software to be considered as true. In particular, we chose 9 up-regulated and 21 down-regulated 
miRNAs (Table 2, reported in italic). Among the up-regulated set of data, 5 miRNAs (139-5p 
P=0.0109; 148a P=0.0040; 193-3p P=0.0013; 330-3p P=0.0003; 455-5p P=0.0109) maintained 
statistical significance, whereas let-7b reached borderline significance (P=0.054). Among the down-
regulated, 3 miRNAs were confirmed as significantly deregulated (miR-129-1-3p, P=0.03; miR-
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129-2-3p, P=0.03; miR-876-5p, P=0.0176). Taking into account the significantly altered miRNAs, 
miRNA-mRNA interaction network analysis through IPA returned three direct interactions: IGF1R 
→ miR-139-5p/miR-455-5p/let-7b, CDK6 → miR-139-5p, CDK6 → let-7b and CD44 → miR-330 
(Figure 23). 
 
 
Figure 23. Integrated miRNA-mRNA regulatory networks by IPA. The red rectangle represents miRNA, while the green circle 
indicated target genes. Arrows denote direct interactions between a miRNA and its target 
 
 
Analysis of the putative binding sequences at 3’UTR target genes - Taking into account that 
miRNAs bind the mRNA at their 3’UTR, we further analyzed the putative target sequence at the 
3’UTRs of IGF1R, CDK6 and CD44 genes, through TargetScan in silico program 
(http://www.targetscan.org). 
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Table 4. Summary of mRNA-miRNA regulatory networks retrieved by IPA software. 
                
  ↑ miRNA (KIT/PDGFRA mutant vs WT GISTs) 
  let-7b let-7c 
miR-139-
5p 
miR-148a-
3p 
miR-152-
3p 
miR-
193b-3p 
miR-195-
5p 
miR-
199b-5p 
miR-330-
3p 
miR-335-
5p 
miR-
455-3p 
miR-455-
5p 
miR-
487b-3p 
miR-
497-5p miR-886-3p 
↓ 
mRNA 
CDK6 IGF1R IGF1R - IGF1R - CDK6 - CD44 IGF1R - NCSTN - IGF1R - 
IGF1R  CDK6    TAB3   EPN2  IGF1R     
CPEB3                             
  ↓ miRNA (KIT-PDGFRA mutant vs WT GISTs) 
  
miR-1225-
3p 
miR-
1237 
miR-129-
1-3p 
miR-129-
2-3p 
miR-15a-
5p 
miR-186-
5p 
miR-191-
5p 
miR-197-
3p 
miR-199a-
5p 
miR-214-
3p 
miR-28-
5p 
miR-30c-
1* 
miR-30e-
5p 
miR-
326 miR-328-3p 
↑ 
mRNA - - - - - - - - - 
LZTS1 
- - - - - 
  
                
  miR-338-
3p miR-34a 
miR-34b-
5p 
miR-424-
5p 
miR-425-
5p miR-450a 
miR-490-
3p 
miR-490-
5p 
miR-491-
5p 
miR-542-
3p 
miR-
542-5p 
miR-590-
5p 
miR-769-
5p 
miR-
876-3p miR-876-5p 
↑ 
mRNA - - - - - - - - 
MMP2 
- - - - - - 
                
 
In bold are highlighted miRNAs confirmed in the validation step; miRNA let 7b had a borderline significance (P = 0.054).  
-: no correspondence between the significant mRNA and verified miRNA targets. 
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As shown in figure 24A, with regard to IGF1R 3’UTR, we identified two potential binding sites for 
miR-139-5p at position 2486-2493 and 3742-3748, two for miR-455-5p at position 3777-3783 and 
4193-4199, and three for let-7b at position 99-105, 2619-2626, 6661-6667. With regard to the 
CDK6 3’UTR, we observed four potential binding sites for miR-139-5p at positions 7989-7995, 
3550-3556, 6966-6972 and 10177-10183 (Figure 24B). On the contrary, we found no potential 
direct binding sites for CD44/miR-330-3p and CDK6/let-7b at their 3’UTR regions. 
 
 
Figure 24. A) IGF1R - miRNA binding sites on its 3’UTR. Computational analysis of the IGF1R 3’UTR showed that miR-139-5p, 
455-5p and let-7b have potential binding sites. Predicted binding sequences of miR-139-5p, 455-5p and let-7b to IGF1R are in red. 
 
 
 
Figure 24. B) CDK6 - miRNA binding sites on its 3’UTR. Computational analysis of the CDK6 3’UTR showed that miR-139-5p 
had four potential binding sites. Predicted binding sequences are in red. 
 
Western blotting analysis - In order to confirm miRNA–mRNA network at the protein level, a 
western blotting analysis was performed. Analysis confirmed IGF1R was strongly expressed in all 
KIT/PDGFRA WT-SDH deficient GIST, while no expression was detected in KIT/PDGFRA mutant 
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cases (Figure 25). With regard to CD44 and CDK6, no change in expression was observed (data not 
shown).  
 
 
Figure 25. Western blotting confirmed a difference in IGF1R expression. Actin was used as internal control 
 
Expression levels of miR-139-5p/miR-455-5p/let-7b - After having confirmed the IGF1R differential 
expression at the protein level in the two subsets of GISTs, we focused our attention on its 
epigenetic network by miR-139-5p, miR-455-5p and let-7b.  
We added 9 new GIST cases to the validation cohort (for a total of 37 GISTs, of which 27 were 
KIT/PDGFRA mutant and 10 were KIT/PDGFRA WT) and checked the expression level of the 3 
miRNAs. Moreover, we evaluated miR-139-5p, miR-455-5p and let-7b expression in two GIST cell 
lines. As highlighted in figure 26, miR-139-5p and miR-455-5p maintained the statistical 
significance, even after Bonferroni correction; let-7b did not maintain a significant difference after 
Bonferroni correction. 
 
 
 
 
 
 
 
 
Figure 26. miR-139-5p and miR-455-
5p expression levels were analysed in 
an extended cohort of 36 GIST 
patients, of which 27 were 
KIT/PDGFRA mutant and 9 were 
KIT/PDGFRA WT /SDH deficient. 
Moreover, we evaluated the same 
miRNAs in two GIST cell lines. 
 
For this reason, our attention was then focused only on miR-139-5p and miR-455-5p and proceeded 
with a luciferase assay to verify interaction between the two miRNAs and IGF1R 3’UTR. 
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Luciferase assay – as shown in figure 27, we observed a reduction of luciferase activity in both 
GIST48 and GIST882 cell lines transfected with pMiRNanoGlo and miRNA mimics with respect to 
cells transfected with the plasmid alone.  
 
Figure 27. Luciferase assay results in GIST48 and GIST882. Control was set as 1. 
 
Site-Directed Mutagenesis - All constructs were sequenced to confirm the deletion; an example is 
showed in figure 28. 
 
 
 
Figure 28. Sanger sequencing was used to confirm presence of miRNA binding site deletion 
 
 
As showed in figure 29, luciferase assay was used to figure out which one between the two binding 
sites is important for miR-139-5p activity. The data highlighted that miR-139-5p regulates IGF1R 
via mainly binding the site in position 2486-2493. 
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Figure 29. Luciferase assay with the 3 constructs (with WT miR-139-5p binding sites, with deletion of the first binding site and 
with deletion of the second one) in presence of miR-139-5p mimic 
 
 
Indeed, deletion of second site (3742-3748), making available only the first one, led to an 80-90% 
reduction of luciferase activity in both the cell lines, compared with cells transfected with a Wt 
construct. This suggests that the first site is the one important in mediating IGF1R modulation.  
On the contrary, deletion of any of the two miR-455-5p binding sites promoted higher luciferase 
activity in both the cell lines, compared to cells transfected with a WT construct (figure 30); 
increase in luminescence is index of a reduction of miRNA binding and activity and vice versa.  
 
 
Figure 30. Luciferase assay with the 3 constructs (with WT miR-455-5p binding sites, with deletion of the first binding site and with 
deletion of the second one) in presence of miR-455-5p mimic. Values of luminescence were reported on Y axis; control was set as 1. 
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Analysis of apoptosis - Figure 31 summarized the results for analysis of apoptotic rate. 
 
 
Figure 31. Results of analysis of apoptotic rate in cells transfected with negative control and cells transfected with 100nM of anti-
miR-139-5p 
 
We did not observed any difference in cells transfected with anti-miR-139-5p or with anti-miR-
455-5p, compared to the ones transfected with negative control. This suggested that miR-139-5p 
and miR-455-5p do not play a role in apoptosis. 
Cell migration assay - We observed that inhibition of miR-139-5p promoted a higher migration 
rate with respect to no transfected cells and transfected with negative control (in figure 32, only 
negative control is showed as control). This is more evident in GIST48 line. We did not highlight 
difference between cells transfected with anti-miR-455-5p and negative control. 
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Figure 32. Migration assay was applied to detect the invasive capacities of GIST48 (A) and GIST882 (C) cells treated or not. 
B) and D). Recover areas were calculated using Image J software 
 
Invasion assay.  We measured the value of OD 570nm; for each cell line, OD value was set as one. 
Invasion assay was applied to assess the invasion capacities of the cells treated or not with anti-
miR-139-5p and anti-miR-455-5p. After transfection, the cell migration ability was increased in the 
cells treated with anti-miR-139-5p (figure 33)  
 
 
Figure 33. Invasion assay was applied to detect the invasive capacities of GIST48 (A) and GIST882 (B) cells treated or not 
 
 
Western blotting - We evaluated IGF1R expression 48 hours after transfection with anti-miR-139-
5p and anti-miR-455-5p. As showed in figure 34, we observed that IGF1R was expressed in the 
cells transfected with anti-miR-139-5p but not with anti-miR-455-5p. Moreover, we evaluated 
IGF1R activation, but no phosphorylation was detected.  
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Figure 34. Expression of IGF1R at the protein level, evaluated through western blotting. 
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5.3. Discussion 
A growing body of literature has shown the importance of miRNAs in a variety of biological 
processes, as well as in cancer development and progression 92. A small number of studies have 
been published focusing on the significance of miRNAs in GIST development, classification, 
diagnosis and prognosis [for a review see ref. 93]. In this context, even more scarce is the knowledge 
about the differences in miRNA expression between KIT/PDGFRA mutant and KIT/PDGFRA WT 
GIST. Basing on these forewords, we integrated multiple expression profiles of miRNA and mRNA 
to construct an original miRNA-mRNA regulatory network. We analyzed gene expression and 
miRNA arrays data comparing KIT/PDGFRA mutant vs KIT/PDGFRA WT GISTs. Taking into 
account that usually mRNA and miRNA expression has an inversion expression (i.e. ↓mRNA is 
associated with ↑miRNA and viceversa), we highlighted the existence of 3 potential regulatory 
networks, IGF1R → miR-139-5p/miR-455-5p/let-7b, CDK6 → miR-139-5p/let-7b, CD44 → miR-
330-3p. Specifically, we identified 7 miRNAs (let-7b, let-7c, miR-139-5p, miR-152-3p, miR-335-
5p, miR-455-5p, and miR-497-5p) that could affect the IGF1R expression.  
In the second step, we performed miRNAs validation in an enlarged cohort of 37 GIST cases. This 
led us to confirm the significant deregulation of miR-139-5p and miR-455-5p, while, let-7b did not 
maintain the statistical significance. For this reason, we focused only on the first two miRNAs and 
proceeded with functional in vitro studies. To this purpose, we used two GIST cell models, GIST48 
and GIST882; the two cell lines are both KIT mutant and may not represent the best model. 
However, unfortunately, GIST cell lines are not commercially available, all the established lines 
harbour KIT mutations and there are not KIT/PDGFRA WT models.  
First, through a luciferase assay we confirmed that both miR-139-5p and miR-455-5p may bind 
IGF1R 3’UTR and regulate its expression. This data suggest that IGF1R could be epigenetically 
modulated by miR-139-5p and miR-455-5p, which are up-regulated in KIT/PDGFRA mutant GISTs 
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and could therefore inhibit IGF1R via binding its 3’UTR. Subsequently, we analyzed the binding 
sites to understand which one is involved in this regulation. With regard to miR-139-5p, the results 
revealed that position 2486-2493 is the key seed sequence, whereas site on position 3742-3748 
could represent an ancillary site not involved in IGF1R regulation. On the contrary, we did not find 
any difference in miR-455-5p binding sites (positions 3782-3788 and 4198-4204); indeed deletion 
of any of the two sites promotes higher luciferase activity compared to the control, which is index 
of diminished miR-455-5p/3’UTR binding. This led us to speculate that both the sites are equally 
important for miR-455-5p activity.  
Finally, we performed a series of functional experiments to clarify the role of miR-139-5p and 455-
5p. With regard to IGF1R, we observed that inhibition of miR-139-5p, but not miR-455-5p, 
restored its expression in both GIST48 and GIST882 lines. In addition, miR-139-5p seems to play a 
role in invasion and migration. Indeed, its inhibition increased cell migration and invasion 
capability in both cell lines.  
In summary, we showed that miR-139-5p is down-regulated in KIT/PDGFRA WT GISTs and 
IGF1R is among the most up-upregulated genes in this subset of patients. In previous studies, 
IGF1R has been identifies as a target to suppress tumor cell proliferation, migration and invasion in 
gliomas, HeLa cells, non-small cell lung cancer, amongst others 94,95,96. MiR-139-5p has been 
widely reported in literature as tumor suppressor 97,98,99; our results are in agreement with these data 
and could represent a novel biomarker in KIT/PDGFRA WT GIST subset. This is the first report on 
the tumor suppressive function of this miRNA in GISTs; in addition, our results confirm the 
regulatory network miR-139-5p/IGF1R. To the best of our knowledge, this is the first time that 
epigenetic regulation is explained at the molecular level in GISTs. In particular our results 
suggested that miR-139-5p may represent a potential onco-miR marker in KIT/PDGFRA WT 
GISTs, characterized by IGF1R epigenetic-enhanced expression, driving the carcinogenesis and 
development of KIT/PDGFRA WT GIST. In this context, epigenetically IGF1R activation and over-
expression would serve the same as the KIT/PDGFRA driver mutation. Therefore, this miRNA 
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signature has the potential to represent an important diagnostic tool and therapeutic target in 
KIT/PDGFRA WT GISTs, and in particular in the SDH-deficient subset. In conclusion, we are 
aware of the limitation of the present study, in particular the small sample size that could have mask 
the significant effect of some of the miRNA, and consequently leading to the non-identification of 
important miRNA-mRNA networks.  
Obviously, further identification of additional aberrantly expressed miRNAs in a larger GIST 
population, and the elucidation of their functional roles will be helpful in understanding the 
pathogenesis of GIST disease, and has the potential to represent a rational therapeutic strategy for 
the treatment of KIT/PDGFRA WT-SDH-deficient GISTs. 
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6. Second aim: Characterization of novel mechanisms of 
pharmacological resistance to a PI3KCA inhibitor from an omic 
point of view 
As widely previously described in the introduction, with the arrival of imatinib, GIST became the 
best example of target therapy in solid tumors 24,21,5. The major part of patients with advanced 
GISTs under imatinib have persistent measurable disease and typically within 24-36 months 
eventually progress 100. During these almost 20 years since imatinib approval, to face emergence of 
pharmacological resistance, a second and a third line – sunitinib and regorafenib, respectively, have 
been introduce in the GIST management. As imatinib, sunitinib and regorafenib are TKIs and act 
with the same mechanism of action. Compared with first-line imatinib, benefits produced by 
sunitinib and regorafenib are quite limited and the majority of patients often experience tumor 
progression; this depends on the emergence of multiple drug resistant KIT mutations within an 
individual tumor 62,101,102,103. Besides TKIs, to date, there are no other therapeutic options and, for 
this reason, the identification of novel druggable targets and a better characterization of resistance 
process may represent a key starting point to fine tune a clinical approach different from TKIs. 
Recently, a phase 1b trial started to evaluate a novel PI3KCA inhibitor - BYL719 (Novartis) - in 
GIST patients who previously failed imatinib and sunitinib (NCT01735968). Indeed, one of the 
strategies to fight resistance in GISTs could be represented by inhibiting PI3K pathway, which is 
downstream of KIT/PDGFRA. This pathway is deregulated in many human cancers, including 
GISTs 104,105,106,107,108. Specifically, BYL719 is a selective inhibitor of the PI3K catalytic p110a 
subunit 109, and showed a significant antitumor effect in patient-derived xenograft models of GIST 
110. This led to a trial for GIST patients, who previously failed imatinib and sunitinib 
(NCT01735968), but it is still ongoing and there are no results yet. The interesting preclinical 
results prompted us to focus our attention on the cells’ behavior treated with this new mo lecule, but 
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not from a canonical point of view. We generate two in vitro models of acquired resistance and 
performed an omics-based analysis by integrating miRNA profiling, RNA-sequencing and 
methylation profiling in sensitive and resistant cells. The aim of this work was to comprehensively 
characterize genomic and transcriptomic changes, which take place during noticing of resistance 
and how cancer cells evolve from drug-sensitive from an omic point of view. 
6.1. Materials and methods 
Cell culture and treatment - Two human established imatinib resistant GIST cell lines, GIST48 and 
GIST48B, were used. Cell lines were kindly provided by Dr Fletcher (Department of Pathology, 
Brigham and Women's Hospital, Harvard Medical School, Boston, MA). GIST48 has a primary, 
homozygous KIT exon 11 missense mutation (V560D) and a heterozygous secondary KIT exon 17 
mutation (D820A), activating kinase loop 111. This cell line was established from a GIST that 
ceased to respond to imatinib, while GIST48B is a subline of GIST48, which expresses KIT 
transcript but not the protein, and preserves activating KIT mutation in all cells 112. Cells were 
cultured in IMDM (Gibco) supplemented with 15% FBS (Gibco) and 1% penicillin (10,000 
U/ml)/streptomycin (10 mg/ml) (Lonza) and maintained at 37°C in a humified atmosphere of 5% 
CO2. To generate BYL719 resistant sublines, GIST48 and GIST 48B were cultured with increasing 
concentrations of BYL719 (Selleckchem), starting with 0.05 µM and to 5 µM. Fresh drug was 
added every 3-4 days and resistant cells, able to grow in 5 µM BYL719, were established after 
about 50 weeks of culture with the drug. GIST48 and GIST48B resistant cells are referred to as 
GIST48-R and GIST48B-R. RNAs and DNAs were isolated at the time zero of each change of 
concentration. KIT-mutant cell lines were authenticated by KIT sequencing and KIT TKI sensitivity 
experiments. GIST cell lines were routinely tested for mycoplasma contamination and were found 
to be negative. 
MTT assay and IC50- IC50 was evaluated with the MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide] assay as previously described 113. Briefly, 1x104 cells were 
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seeded in a 96 well plate, and the day after serially diluted BYL719 was added by medium 
replacement. After 48h, the cells were washed with HBSS and then incubated with MTT (5 mg/mL) 
in HBSS for 2 h. After removal of MTT and further washing, the formazan crystals were dissolved 
with isopropanol. The amount of formazan was measured (570 nm) with a spectrophotometer 
(TECAN®, Spectra model Classic, Salizburg, Austria). 
DNA isolation - Genomic DNA was extracted from each cell lines using QIAamp DNA Mini Kit 
(QIAGEN), according to the manufacturer’s recommendations 
KIT and PI3KCA DNA analysis -  Mutational analyses of KIT (exons 9, 11 13, 14, 17 and 18) and 
PI3KCA (exons 9 and 20) were performed on genomic DNA from GIST48, GIST48B, GIST48-R 
and GIST48B-R. Briefly, each exon was amplified with PCR amplification using specific primer 
pairs. Then, PCR products were purified and sequenced on both strands using the Big Dye 
Terminator v1.1 Cycle Sequencing kit (Applied Biosystems). Sanger sequencing was performed on 
ABI 310 Genetic Analyzer (Applied Biosystems). 
RNA isolation - Total RNA was isolated from parental (GIST48 and GIST48B) and BYL719 
resistant (GIST48-R and GIST48B-R) cultured cells using RNeasy® mini Kit (QIAGEN) following 
manufacturer’s instructions.  
ABC transporter genes expression levels - Total RNA was retro-transcribed to cDNA using High 
Capacity RNA-to-cDNA kit. The cDNA was then loaded in TaqMan® Human ABC Transporter 
Arrays, which allow quantitative gene expression analysis of human ABC transporter genes 
important in drug discovery. The array contains 64 gene expression assays (50 targets and 14 
controls) arrayed in triplicate in 384 wells. Arrays were normalized using GAPDH and 18S as 
endogenous controls, and the data were analyzed using the 2−ΔΔCt method. Genes with Ct>35 were 
considered as not expressed and excluded from further analysis 
RNA sequencing- Whole-transcriptome RNA libraries were prepared in accordance with Illumina's 
TruSeq RNA Sample Prep v2 protocol (Illumina, San Diego, California). Poly(A)-RNA molecules 
from 500 ng of total RNA were purified using oligo-dT magnetic beads. Subsequently, mRNA was 
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fragmented and randomly primed for reverse transcription followed by second-strand synthesis to 
generate double-stranded cDNA fragments. These cDNA fragments went through a terminal-end 
repair process and ligation using paired-end sequencing adapters. The products were then amplified 
to enrich for fragments carrying adapters ligated on both ends and to add additional sequences 
complementary to the oligonucleotides on the flow cell, thus creating the final cDNA library. 12pM 
paired-end libraries were amplified and ligated to the flowcell by bridge PCR, and sequenced at 
2x75bp read length for RNA, using Illumina Sequencing by synthesis (SBS) technology. 
Bioinformatic analysis - After demultiplexing and FASTQ generation (using bcltofastq function 
developed by Illumina), the paired-end reads were trimmed using AdapterRemoval 
(https://github.com/MikkelSchubert/adapterremoval) with the aim of removing stretches of low 
quality bases (<Q10) and Truseq/Nextera rapid capture adapters present in the sequences. 
Sequences coming from RNA-seq were mapped with TopHat/BowTie pipeline and PCR or optical 
duplicates were removed with the function rmdup of Samtools.  
SNV calling - Variant calling was performed with SAMtools and SNVMix2, thus identifying all the 
point mutations and INDELs. Variants included in dbSNP and 1000 Genomes, ExAc and EVS with 
frequency > 1% were excluded. All variants from the matched normal-tumor pairs that were unique 
in the tumor sample were called as somatic.  
Gene expression analysis - In order to compare the gene expression profile between sensitive and 
BYL-719 resistant GIST cell lines, RNA seq data were analyzed After the alignment procedure, the 
BAM file obtained was manipulated with SAMtools in order to remove the optical/PCR duplicate, 
and to sort and index it. The function HTSeq-count (Python package HTSeq) was adopted to count 
the number of reads mapped (cpm) on known genes, included in the Ensembl release 72 annotation 
features (http://www.ensembl.org). 
miRNA expression evaluation - 300 ng of total RNA were reverse transcribed using TaqMan® 
MicroRNA reverse transcription kit (ThermoFisher Scientific) using Megaplex RT primers Human 
Pool A and Pool B. cDNAs were load on TaqMan Arrays Human MicroRNA A and B Cards 
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(ThermoFisher Scientific) and run on 7900HT Real-Time PCR system, in accordance with the 
manufacturer’s procedure. The miRNA data were analyzed with SDS Relative Quantificat ion 
Software version 2.4. (Applied Biosystems) and miRNAs with Ct>35 were considered as not 
expressed and excluded from further analysis; miRNA expression levels were normalized using U6 
and RNU48 as endogenous controls. Normalization was carried out by subtracting the mean Ct 
from individual Ct values. R-Bioconductor package Limma was adopted to evaluate the differential 
expression profile between the parental and BYL719 resistant GIST cell lines 
Global methylation profile-. 600 ng of genomic DNA per sample were bisulfite-converted using EZ 
DNA methylation Kits (Zymo research), and DNA methylation was measured using the Illumina 
Infinium HD Methylation Assay with Infinium MethylationEPIC BeadChips according to 
Illumina’s protocol. Raw data (idat files) were processed in R Bioconductor (minfi27). Quality of 
each sample was analyzed and probe signal was removed when the detection p-value was above 
0.05, or >1% of the dataset contained no data, or if probes contained single nucleotide 
polymorphisms. None of the samples included in the study was flagged as outliers 114. Statistical 
analyses were carried out using GenomeStudio, normalizing idats with the controls provided by 
Illumina; the methylation score of each CpG is represented as a β-value and differences between 
βvalues of treated and untreated cells represent alteration in methylation level. The CpGs selected 
were those absolute methylation differential value of >0.2 or <-0.2 115,114. To identify CpGs on 
promoter regions, we considered as UCSC refgene group only TSS200 or TSS1500. 
Identification of validated miRNA targets - Targets of significant miRNAs were identified through 
specific in silico tools which allow predicting the most probable targets. Six programs were used 
(TargetScan, mirbase, MIRanda, mirtarget2, PicTAR, and miRTarBase), and the targets were 
considered reliable if at least 4 out of 6 were in agreement.  
miRNA and mRNA correlation - Using these information, miRNA and mRNA arrays were analysed 
to highlight pairs of mRNA/miRNA that were discordant (UP vs DOWN and vice versa). Potential 
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miRNA-mRNA interactions and miRNA/mRNA expression profiles were used to construct 
functional interaction networks. 
Methylation profile and gene expression correlation - To integrate methylation profile and gene 
expression profile (GEP), we considered only CpGs on promoter regions which shown an absolute 
methylation differential value of >0.2 or <-0.2 in parental lines versus BYL719 resistant ones; 
promoter regions were defined as the upstream 1500 bp and downstream 200 bp from the 
transcription start site (TSS) of each gene. For each differentially methylated gene, we checked the 
expression level deriving from RNA sequencing  
6.2. Results 
KIT and PI3KCA analysis - We did not detect additional mutations in BYL719 resistant cell lines in 
KIT gene. With regard to PI3KCA, we specifically analysed exon 9 and exon 20 - both codifying 
for the catalytic p110a subunit - given that these exons are mutational hotspots in a wide portion of 
human cancers 116 117. All the samples were WT.  
ABC transporter genes - Given the well-recognized role of ABC transporter genes in mediating 
drug resistance, we firstly analyzed a custom panel of 50 genes in sensitive and resistant cell lines. 
However, we could not observed any significantly deregulated gene after treatment with BYL719. 
RNA-seq: Gene expression - For this reason, we decided to carry on a comparative analysis between 
GIST48 and GIST48B vs GIST48-R and GIST48B-R. The comparative analysis showed 95 
differentially expressed genes with a false discovery rate =0 and p-value ≤0.001 (Table 5)  
Table 5. List of genes differentially expressed in parental and resistant cell lines 
Up-regulated genes in BYL719 resistant cell lines Down-regulated genes in BYL719 resistant cell 
lines 
Gene_name logFC Pvalue FDR Gene_name logFC Pvalue FDR 
H19 2.23 8.61E-12 1.08E-07 C16orf89 -2.21 0.000000 0.000001 
RAB3IP 3.23 1.19E-09 3.93E-06 MXRA5 -1.90 0.000000 0.000004 
ANXA3 1.81 8.24E-08 0.000148 BRINP1 -3.82 0.000000 0.000121 
LXN 2.57 2.9E-07 0.000304 CUX2 -2.27 0.000000 0.000215 
CHAC1 2.41 1,00E-06 0.000841 SLC4A7 -1.57 0.000000 0.000215 
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TNFSF10 3.12 1.53E-06 0.001043 PCSK6 -1.78 0.000000 0.000215 
CLMN 2.40 1.8E-06 0.001078 SGK1 -2.46 0.000001 0.000535 
ACSM3 2.26 5.71E-06 0.002987 GPC2 -1.79 0.000001 0.001010 
PDE5A 1.52 9.67E-06 0.004328 FN1 -1.54 0.000003 0.001451 
DSG2 2.60 1.39E-05 0.005618 RHBDF1 -1.43 0.000007 0.003245 
ASNS 1.30 1.58E-05 0.00619 SAMD11 -1.38 0.000008 0.003622 
PSAT1 1.48 1.96E-05 0.007033 VCAM1 -1.67 0.000017 0.006486 
SNX10 2.00 2.51E-05 0.008495 ID3 -1.69 0.000019 0.006898 
LMO4 1.29 2.64E-05 0.008495 SMAD9 -1.28 0.000029 0.008963 
SEMA3C 2.39 3,00E-05 0.009034 SLC14A1 -3.15 0.000030 0.009034 
GLRB 2.02 3.22E-05 0.009306 TSHZ2 -2.18 0.000033 0.009306 
ADD2 1.62 4.99E-05 0.012541 MME -1.47 0.000035 0.009897 
EGR1 2.46 7.05E-05 0.017026 RP11-54O7.1 -2.01 0.000041 0.010885 
MAL2 2.82 7.84E-05 0.017893 PHF2P2 -1.39 0.000042 0.011066 
PRIMA1 2.06 8.88E-05 0.018896 TYRO3 -1.42 0.000097 0.019908 
TBC1D2B 1.47 9.25E-05 0.019348 NUAK1 -1.45 0.000105 0.020765 
GAB2 2.19 0.000108 0.020816 PHLDB2 -1.64 0.000106 0.020765 
PROCR 1.89 0.000129 0.023094 DACT3 -1.43 0.000104 0.020765 
ICA1 2.05 0.000132 0.023302 GTF2IP3 -2.01 0.000109 0.020816 
PRKCQ-AS1 1.56 0.000142 0.024358 ID2 -1.25 0.000117 0.021688 
DOCK9 1.77 0.000171 0.0276 EFNB2 -1.59 0.000137 0.023811 
LAMP3 1.22 0.000232 0.035097 IQGAP2 -1.14 0.000144 0.024358 
TRIB1 1.25 0.000232 0.035097 RBM18 -1.17 0.000170 0.027600 
TBC1D8B 1.62 0.000266 0.038374 SOSTDC1 -1.84 0.000189 0.030100 
SFRP1 1.10 0.000358 0.048283 F2R -1.48 0.000225 0.034926 
TNFAIP8 1.29 0.000407 0.052689 ADGRD1 -1.54 0.000262 0.038374 
SAMD12 2.06 0.000424 0.053714 GAREM -1.46 0.000297 0.042399 
JUNB 1.43 0.000444 0.055782 SOX4 -1.23 0.000306 0.043207 
DAAM2 1.21 0.000483 0.05878 SMAD6 -1.21 0.000350 0.047754 
IGSF3 1.13 0.000487 0.05878 SH3BP5-AS1 -1.66 0.000347 0.047754 
LGI2 1.90 0.000521 0.061597 PREX2 -1.06 0.000369 0.049242 
CALB2 1.72 0.000525 0.061597 BCRP3 -1.76 0.000420 0.053714 
PDE3B 1.39 0.000552 0.063588 COL16A1 -1.15 0.000449 0.055782 
GPC3 1.71 0.000574 0.064953 PDLIM3 -1.45 0.000463 0.056947 
TNFRSF19 2.17 0.000571 0.064953 ADAMTS2 -1.65 0.000512 0.061195 
FOXP2 1.57 0.00061 0.06843 WTIP -1.16 0.000531 0.061674 
BST2 1.18 0.000619 0.068795 MYO1B -1.27 0.000626 0.068960 
HUNK 1.30 0.000647 0.070631 SORBS1 -1.55 0.000703 0.075396 
FAM19A4 1.76 0.000709 0.075396 PPARGC1B -1.01 0.000794 0.081682 
ARRB1 1.27 0.000737 0.07712 ATOH8 -2.31 0.000808 0.082507 
CCDC181 1.55 0.000893 0.088251 ZDHHC11 -1.33 0.000832 0.084194 
GLTSCR2 0.98 0.001004 0.098527 CTGF -1.16 0.000869 0.087235 
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FOS 2.77 0.001014 0.098663     
 
In particular, 48 genes were up-regulated, while 47 genes were down-regulated. The significant 
DEGs are reported in table 5. GO functional enrichment analysis of up-regulated and down-
regulated genes are showed in figure 35A. The top deregulated genes are shown in figure 35B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. A) GO functional enrichment analysis of up-regulated and down-regulated genes. B) The top deregulated genes 
 
 
SNV calling - Compared to the parental cell lines, we were able to identified 4 and 7 novel 
mutations respectively in GIST48-R and GIST48B-R (Table 6); the genes with novel mutations 
were not reported in literature as involved in PI3KCA downstream via. No one among those was in 
common between the two models. Therefore, we concluded that resistance to BYL719 was not 
linked to acquired mutations, as frequently happens in GISTs under TKIs.  
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Table 6. Novel acquired mutations in BYL719 resistant cells 
GIST48 vs GIST48-R GIST48B vs GIST48B-R 
Gene Exon AA change Gene Exon AA change 
KIFC2 exon17 p.R732C FRY exon5 p.D168Y 
RIF1 exon19 p.V666A PDGFB exon3 p.R51H 
DPF1 exon9 p.C313G SYT14 exon6 p.V359A 
RPGR exon6 p.Q171R EEF2KMT exon2 p.H52Q 
   RARS2 exon1 p.C11X 
   DCHS1 exon2 p.R168C 
 
miRNA expression - The array highlighted a total of 44 deregulated miRNAs out of the 754 
analyzed with a p-value <0.05, However, after correction, only 13 miRNAs maintained the 
statistical significance. In particular, the expression of 2 miRNAs was strongly up-regulated (has-
miR-190b and has-miR-299-5p), and 11 miRNAs were down-regulated in resistant GIST cell lines 
compared to parental ones. All the differentially expressed miRNAs are reported in table 7.  
Table 7. The most significant deregulated 
miRNAs 
miRNA Pvalue Adjusted Pval 
hsa-miR-1243 2.94E-06 0.002232799 
hsa-miR-520c-3p 1.27E-05 0.003316809 
hsa-miR-190b 1.31E-05 0.003316809 
hsa-miR-1289 2.72E-05 0.005164803 
hsa-miR-1247-5p 0.000118 0.016017348 
hsa-miR-22-3p 0.000126 0.016017348 
hsa-miR-1267 0.000188 0.020418143 
hsa-miR-299-5p 0.000237 0.022470219 
hsa-miR-125b-5p 0.000294 0.024789505 
hsa-miR-656-3p 0.000447 0.033993852 
hsa-miR-331-5p 0.000591 0.040837133 
hsa-miR-149-3p 0.000868 0.054998185 
hsa-miR-30d-5p 0.001126 0.065812471 
 
Hierarchical clustering of all samples separated sensitive and resistant GIST cell lines into two 
distinct clusters (Figure 36A).  
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Figure 36. A) Hierarchical clustering analysis of miRNA expression. B) miRNA regulatory roles and identification of controlled 
pathways through miRPath 3.0 
 
Through miRPath 3.0 we assessed miRNAs regulatory roles and identified their pathways 118. 
Interestingly, among the pathways potentially modulated by those deregulated miRNAs 
(summarized in figure 36B), the most significant and with the greatest number of target genes, are 
PI3K/AKT- MAPK and Ras cascades, which are involved in BYL719 mechanism of action. 
Global methylation profile- We performed a genome-wide DNA methylation profiling in both 
parental and resistant GIST48 and GIST48B cell lines to determine whether acquired resistance 
involves modifications in DNA methylation. We identified 3305 CpGs differentially methylated pre 
and post treatment (Δβ value <-0.2 or >0.2). Figure 37 shows the unsupervised hierarchical cluster 
analysis of the demethylated genes; the analysis divided the sample set into two main clusters: 
sensitive and resistant cell lines (Figure 37).  
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Figure 37. The heatmap shows the DNA methylation profiles of parental and resistant cell lines (Δβ value <-0.2 or >0.2). 
 
 
Interestingly, as shown in figure 38A, B and C, the resistant cells showed significantly more 
promoter hypermethylation of the CpG islands than their parental counterparts.  
 
 
Figure 38. A) Box-plots show the β values of the CpGs at the promoters (only CpG islands); a general hypermethylation is more 
common in the resistant cell lines. B, C) Scatter plots of genome-wide DNA methylation levels (β). To highlight the general 
hypermethylation, in the two figures are reported the CpG islands with Δβ value <-0.2 or >0.2. 
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Among the 3305 CpGs, 2817 were hypermethylated, whereas 488 were hypomethylated. Among 
the hypermethylated CpGs, 547 were in promoter regions of 379 genes. With regard to the 
hypomethylated sites, 102 were in promoter regions of 70 genes. 
miRNAs and mRNAs arrays correlation - To construct miRNAs-DEGs networks, we downloaded 
the experimentally verified associations between human miRNAs and their targets from 
miRTarBase, which encloses more than 400000 miRNAs-target interactions collected by manually 
surveying pertinent literature after systematic data mining of the text. This dataset contains 
miRNAs-target interactions consisting of 4076 miRNAs and 23054 mRNAs 119. The results are 
reported in figure 39. 
.  
Figure 39. miRNAs-DEGs networks 
 
 
Among the 13 deregulated miRNAs retrieved by our data, 7 (miR-331-5p, miR-125b-5p, miR-
520c-3p, miR-1289, miR-299-5p, miR-30d-5p, miR-149-3p) had verified associations with their 
targets. However, taking into account of the typical inverse relationship between miRNAs and 
targets’ expression, we were able to identify 8 mRNA-miRNA networks (Figure 39). 
Methylation and mRNAs arrays correlation - We then integrated global methylation profile with 
DEGs. Some genes showed an association between changes in promoter hypermethylation and 
changes in gene expression. Among the genes with the strongest gene promoter hypermethylation 
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and concomitant increase in gene expression were: Calmin (CLMN), which encodes a member of 
the hedgehog-interacting protein family; Myelin and Lymphocyte protein (MAL), which encodes 
the T-lymphocyte maturation-associated protein and functions in T-cell differentiation. On the 
contrary, promoter hypermethylation and concomitant Teashirt zinc finger homeobox 2 (TSHZ2) 
down-regulation was observed, whereas, PSAT1, Phosphoserine aminotransferase 1, showed strong 
promoter hypomethylation associated with increased gene expression after treatment. 
Integration of miRNAs, methylation profiles and gene expression - Finally, we integrated all the 
data deriving from GEP, miRNAs and methylation profiles. As mentioned before, regarding to gene 
expression modulation by miRNAs, we considered the canonical inverse correlation. We found a 
gene - PSAT1- up-regulated in resistant cell lines, which showed promoter hypomethylation and 
was potentially modulated by miR-125b-5p (Figure 40) (These results are from Ravegnini et al, 
2019, Submitted). 
 
 
Figure 40. Integration of GEP, miRNAs and methylation profiles. In grey are shown genes and miRNAs with the same trend 
of expression, which were excluded. Red and green indicate respectively a down-regulation and an up-regulation 
 
 
. 
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6.3. Discussion 
GISTs represent a worldwide paradigm of target therapy. The introduction of imatinib in clinic has 
deeply revolutionized the GIST management, leading them from incurable disease to be a sort of 
chronic disease. Imatinib showed terrific improvement in prognosis, however, as often happens 
with TKIs, after a certain period, the majority of patients develop acquired mutations and progress. 
To contain the tumor progression, in these last 20 years, a second - sunitinib - and a third – 
regorafenib – line therapy have been introduced; unfortunately, all these treatments act with the 
same mechanism of action and the most of patients progress even under the third line. To date, 
unfortunately, there are no therapeutic options for whom have failed imatinib, sunitinib and 
regorafenib; for these reasons, it is pivotal and mandatory to individuate novel molecules and 
strategies to overcome the inevitable upcoming resistance. Recently, a new trial started for GIST 
patients who previously failed treatment with imatinib and sunitinib (NCT01735968). The trial is 
still ongoing but there are no published results. However, the preclinical results have shown 
promising results 110. Our aim was to comprehensively characterize genomic and transcriptomic 
changes taking place during noticing of resistance, and understand how cancer cells evolve from 
being drug-sensitive to drug resistant, from an omic point of view. We generate two in vitro GIST 
models of acquired resistance to BYL719 and performed an omics-based analysis by integrating 
miRNAs profiling, RNA-seq and methylation profiling in sensitive and resistant cells.  
The first difference that we observed compared with the standard TKIs treatment was the lack of 
novel mutations in BYL719 resistant cells. This is a quite novel mechanism in GISTs, in which 
drug resistance is usually largely due to accumulation of additional kinase domain mutations 110. 
Then, we took into account that among the known mechanisms of drug resistance, the 
overexpression of genes involved in drug efflux or transport is among the most common 120,121,122. 
For this reason, we analyzed a precast panel of 50 well-characterized ABC transporters genes. 
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However, we could not observe any significant difference in resistant cell lines compared to the 
parental ones. The next step was then a deep characterization of these novel models of acquired 
resistance. Through RNA-seq, we could evaluate the appearance of additional point mutations or 
INDELs. Although novel alterations were found in resistant lines, however no mutations were 
shared by both models or harbored on hot-spot genes (including PI3KCA, KIT, or downstream 
effectors). This prompted us to assume that BYL719 resistance could be mediated by epigenetic 
mechanisms. In literature is widely reported that epigenetic modifications may represent alternative 
mechanisms to evade the pharmacological response 123,124,125. Different trials evaluating epigenetic 
therapies in solid tumors as drug resistance modulators are ongoing 123; in GISTs, many research 
efforts have been made to offer therapeutic options to bypass TKIs resistance. In recent years, 
epigenetic treatments raised among the future perspective 126,127, however, results are still at an early 
stage and further investigations are pivotal in this novel field in GISTs.  
Here, through an omic approach, we characterized a peculiar resistance mechanism involving 
epigenetic alterations. Integrating miRNAs and methylation profiles with gene expression 
deregulation, we identified overexpression of PSAT1 as potentially modulated by its promotor 
hypomethylation and by downregulation of miR-125b-5p. Interaction between miRNAs, 
methylation and gene expression have been previously described in cancer 128, but not in GISTs. 
Over-expression of PSAT1, which encodes for phosphoserine aminotransferase 1, has been reported 
as involved in resistance in different tumors, including colorectal and pancreatic cancer, melanoma, 
and non-small cell lung cancer 129,130. PSAT1 belongs to serine biosynthesis pathway, which is a 
key actor in nucleotide and amino acid metabolism and specifically, the folate cycle contributes to 
nucleotide metabolism. The folate cycle provides nucleotide pool replenishment during cell 
proliferation, and DNA damage induces the production of nucleotides 130. Moreover, serine 
synthesis enzyme levels have been shown to increase under conditions of DNA damage and 
genomic instability 130,131. In addition, recently, Labuschagne et al reported that serine, but not 
glycine, supports one-carbon metabolism and proliferation of cancer cells 132. GIST48-R and 
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GIST48B-R were characterized by up-regulation of PSAT1 and this could represent an advantage 
for resistant cells, which have to find novel ploys to live. Here, we showed that PSAT1 over-
expression is modulated by both methylation and miRNAs. It is plausible that these epigenetic 
mechanisms may act concurrently or in a mutual manner, with the final goal to increase PSAT1 
level. Among the genes with a differential methylation level, we found TSHZ2, which showed a 
down-regulation in resistant cells. TSHZ2, a zinc-finger homeobox nuclear protein, is supposed to 
be a tumor suppressor and is down-regulated in breast cancer 133. Interestingly, Yamamoto et al, 
investigated the methylation level of TSHZ2 promoter, but they were not able to observe difference 
with respect to normal tissue, leaving a question of how TSHZ2 is down-regulated. On the contrary, 
we identified an epigenetic contribution for TSHZ2 regulation. We speculated that TSHZ2 might 
bind transcriptional regulators that control the expression of crucial genes in tumorigenesis and 
resistance acquisition. With regard to miRNAs deregulation, we identified 13 miRNAs significantly 
altered in resistant cells. Through miRPath 3.0 we assessed miRNA regulatory roles and identified 
the pathways. Interestingly, among the pathways potentially modulated by those deregulated 
miRNAs, the most significant and with the greatest number of target genes, were PI3K/AKT- 
MAPK and RAS cascades, which are involved in BYL719 mechanism of action. Integrating 
miRNA array and GEP, 5 miRNAs targeted 8 genes (TRIB1, GAB2, SNX10, SAMD12, JUNB, 
GPC3, SOX4). Among those genes, some have been reported involved in PI3K/AKT signaling 
pathway. TRIB1 is a downstream effector of PI3K 134. GAB2, Grb2-associated binder 2, belong to a 
family of scaffolding or docking adaptor proteins; GAB2 cooperates with PI3K/AKT pathway in 
promoting malignant behavior in cells 135,136.  
In conclusion, we identified a peculiar and novel mechanism of resistance in GISTs. Unfortunately, 
at the moment, we do not have patients in treatment with BYL719 to verify this preclinical data. 
However, these results suggest the existence of alternative pathways of resistance in GISTs and 
they should be take into account as alternative adaptive mechanism  
7. Conclusion 
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7. Conclusion 
In the last two decades, the research has progressively focused its attention on epigenetics. It is now 
clear that both genetic and epigenetic alterations are involved and contribute to cancer pathogenesis, 
development, progression, as well as treatment outcome. The knowledge in epigenome is 
continuously growing and we are gradually figuring out its importance in regulating gene 
expression and biological processes. However, to date, clinical translation has been very scarce, 
therefore there is an urgent need to translate the findings.  
GISTs are rare sarcoma tumors, which represent the most common mesenchymal tumor of the GI 
tract, with an incidence of ~1-1.5 new cases/100000 per year.  
In 2018, during the ESMO Sarcoma and GIST Symposium, epigenetics has been included among 
the new avenues in soft tissue sarcomas and GISTs 137. In GISTs, excluding methylation, which has 
been studied more extensively than the other two epigenetic mechanisms (miRNAs and histones 
modifications), the advances have been quite scarce. 
The research of my PhD project aimed to deeper feature the knowledge on epigenetics in GIST. 
Specifically, during my PhD program, the research had two aims; I) the first aim was to investigate 
and characterize the differences in miRNAs expression levels, comparing KIT/PDGFRA mutant and 
KIT/PDGFRA WT GISTs. II) Secondly, we aimed to elucidate mechanisms of pharmacological 
resistance to a PI3KCA inhibitor – BYL719 – in trial at Sant’Orsola Malpighi Hospital for GIST 
patients who previously failed imatinib and sunitinib – the first and the second lines approved for 
GIST. Indeed, all the treatment lines so far approved in GISTs are TKIs, showing a similar 
mechanism of action. 
With regard to the first goal, we identified, for the first time in GIST, an epigenetic mechanism 
involved in regulating the IGF1R expression. In particular, in agreement with the literature, our data 
revealed that miR-139-5p has a role of tumor suppressor and its inhibition promoted cell migration 
and invasion.  
7. Conclusion 
________________________________________________________________________________ 
With regard to the second aim, through an omic approach in in vitro models, we characterized a 
mechanism of resistance involving epigenetic alterations. Specifically, after having confirmed the 
absence of resistance mutations, we integrated miRNAs and methylation profiles with gene 
expression deregulation. This led us to speculate that BYL719 resistance could be mediated by 
alternative mechanisms, which, similarly to mutations, confer advantages to the cells.  
 
Herein we showed that epigenetics in GIST could be more important than it has been thought so far. 
In particular, we showed that epigenetic mechanisms are involved in the pathogenesis, as well as in 
resistance. This highlights the importance to better understand the biology underlying this tumor. In 
addition, considering the emergence of new epigenetic therapies in solid tumors as drug resistance 
modulators, this could represent a chance too important to miss. 
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